WHO/MHP/HPS/EML/2023.02 

© World Health Organization 2023  

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence 
(CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).  

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is 
appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific 
organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work 
under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer 
along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible 
for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.  

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World 
Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). 

Suggested citation. Web Annex A. World Health Organization Model List of Essential Medicines – 23rd List, 2023. In: The selection and 
use of essential medicines 2023: Executive summary of the report of the 24th WHO Expert Committee on the Selection and Use of 
Essential Medicines, 24 – 28 April 2023. Geneva: World Health Organization; 2023 (WHO/MHP/HPS/EML/2023.02). Licence: CC BY-
NC-SA 3.0 IGO. 

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. 

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use 
and queries on rights and licensing, see http://www.who.int/about/licensing.  

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is 
your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk 
of claims resulting from infringement of any third-party-owned component in the work rests solely with the user. 

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of 
any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or 
concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which 
there may not yet be full agreement. 
 
The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by 
WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary 
products are distinguished by initial capital letters. 

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published 
material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of 
the material lies with the reader. In no event shall WHO be liable for damages arising from its use.  

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the 
policies of WHO. 

The recommendations contained in this publication are based on the advice of independent experts, who have considered the best 
available evidence, a risk–benefit analysis and other factors, as appropriate. This publication may include recommendations on the use 
of medicinal products for an indication, in a dosage form, dose regimen, population or other use parameters that are not included in the 
approved labelling. Relevant stakeholders should familiarize themselves with applicable national legal and ethical requirements. WHO 
does not accept any liability for the procurement, distribution and/or administration of any product for any use. 

  



WHO Model List of Essential Medicines – 23rd List (2023) 

Explanatory notes 
The core list presents a list of minimum medicine needs for a basic health-care system, listing the most efficacious, safe and 
cost–effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future 
public health relevance, and potential for safe and cost-effective treatment. 
 
Where the [c] symbol is placed next to an individual medicine or strength of medicine on the core list it signifies that there is 
a specific indication for restricting its use to children. 
 
The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring 
facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed 
as complementary on the basis of consistent higher costs or less attractive cost-effectiveness in a variety of settings.  
 
Where the [c] symbol is placed next to an individual medicine or strength of medicine on the complementary list it signifies 
that the medicine(s) require(s) specialist diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist 
training for their use in children. 
 
The square box symbol () is intended to indicate therapeutic alternatives to the listed medicine that may be considered for 
selection in national essential medicines lists. Alternatives may be individual medicines, or multiple medicines within a 
pharmacological class or chemical subgroup, defined at the 4th level of the Anatomical Therapeutic Chemical (ATC) 
classification, which have similar clinical effectiveness and safety. The listed medicine should be the example of the class or 
subgroup for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine 
that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where 
there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at 
the lowest price, based on international drug price information sources. Not all square box listings are applicable to medicine 
selection for children. A square box is not used to indicate alternative generic brands of the same small molecule medicines, 
nor alternative biosimilars of biological medicines. However, the selection and use of quality-assured generics and biosimilars 
of essential medicines at country level is recommended. 
 
National lists should not use a similar symbol and should be specific in their final selection, which would depend on local 
availability and price.  
 
The a symbol indicates that there is an age or weight restriction on use of the medicine; details for each medicine can be 
found in Table 1.1. 
 
The presence of an entry on the Essential Medicines List carries no assurance as to pharmaceutical quality. It is the 
responsibility of the relevant national or regional drug regulatory authority to ensure that each product is of appropriate 
pharmaceutical quality (including stability) and that, when relevant, different products are interchangeable. 
 
For recommendations and advice concerning all aspects of the quality assurance of medicines see the WHO website 
https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-
pharmaceuticals/guidelines/quality-assurance  
 
Medicines and dosage forms are listed in alphabetical order within each section and the order of listing does not imply 
preference for one form over another. Standard treatment guidelines should be consulted for information on appropriate 
dosage forms. 
 
The main terms used for dosage forms in the Essential Medicines List can be found in Table 1.2. 
 
Definitions of many of these terms and pharmaceutical quality requirements applicable to the different categories are 
published in the current edition of The International Pharmacopoeia. https://www.who.int/teams/health-product-and-policy-
standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/pharmacopoeia.  



WHO Model List of Essential Medicines – 23rd List (2023)  

1. ANAESTHETICS, PREOPERATIVE MEDICINES AND MEDICAL GASES 

1.1 General anaesthetics and oxygen 

1.1.1 Inhalational medicines 

halothane  Inhalation. 

isoflurane  Inhalation. 

nitrous oxide Inhalation. 

oxygen Inhalation (medical gas).  

sevoflurane Inhalation. 

1.1.2 Injectable medicines 

ketamine Injection: 50 mg/mL (as hydrochloride) in 10 mL vial. 

 propofol 

Therapeutic alternatives: Injection: 10 mg/mL; 20 mg/mL. 

- thiopental 

1.2 Local anaesthetics 

Injection: 0.25%; 0.5% (hydrochloride) in vial.  
 bupivacaine 

Injection for spinal anaesthesia: 0.5% (hydrochloride) in 4 mL 
Therapeutic alternatives to be reviewed  ampoule to be mixed with 7.5% glucose solution. 

Injection: 1%; 2% (hydrochloride) in vial. 

 lidocaine Injection for spinal anaesthesia: 5% (hydrochloride) in 2 mL 
ampoule to be mixed with 7.5% glucose solution. 

Therapeutic alternatives to be reviewed  
Topical forms: 2% to 4% (hydrochloride). 

Dental cartridge: 2% (hydrochloride) + epinephrine 1:80 000. 

lidocaine + epinephrine (adrenaline)  Injection: 1%; 2% (hydrochloride or sulfate) + epinephrine 
1:200 000 in vial. 

Complementary List 

Injection: 30 mg/mL (hydrochloride) in 1 mL ampoule. 

ephedrine (For use in spinal anaesthesia during delivery, to prevent 
hypotension). 

1.3 Preoperative medication and sedation for short-term procedures 

atropine Injection: 1 mg (sulfate) in 1 mL ampoule. 

Injection: 1 mg/mL. 
 midazolam 

Oral liquid: 2 mg/mL [c]. 
Therapeutic alternatives to be reviewed  

Tablet: 7.5 mg; 15 mg. 

morphine Injection: 10 mg (sulfate or hydrochloride) in 1 mL ampoule. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 1 



WHO Model List of Essential Medicines – 23rd List (2023)  

1.4 Medical gases 

Inhalation  

For use in the management of hypoxaemia. 
oxygen* 

*No more than 30% oxygen should be used to initiate resuscitation 
of neonates less than or equal to 32 weeks of gestation. 

2. MEDICINES FOR PAIN AND PALLIATIVE CARE 

2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) 

Suppository: 50 mg to 150 mg. 
acetylsalicylic acid 

Tablet: 100 mg to 500 mg. 

Oral liquid: 100 mg/5 mL [c], 200 mg/5 mL. 

ibuprofen a Tablet: 200 mg; 400 mg; 600 mg. 

a Not in children less than 3 months. 

Oral liquid: 120 mg/5 mL or 125 mg/5 mL**, 250 mg/5 mL [c]. 

**The presence of both 120 mg/5 mL and 125 mg/5 mL strengths on the 
same market would cause confusion in prescribing and dispensing and 
should be avoided. 

Suppository: 100 mg, 250 mg [c]. 
paracetamol (acetaminophen)* 

Tablet: 250 mg, 325 mg, 500 mg. 

Tablet (dispersible): 100 mg, 250 mg [c]. 

*Not recommended for anti-inflammatory use due to lack of proven 
benefit to that effect. 

2.2 Opioid analgesics 

codeine Tablet: 30 mg (phosphate). 

Transdermal patch: 12 micrograms/hr; 25 micrograms/hr; 

fentanyl* 50 micrograms/hr; 75 micrograms/hr; 100 micrograms/hr. 

*For the management of cancer pain 

Granules (slow release; to mix with water): 20 mg to 200 mg 
(morphine sulfate). 

Injection: 10 mg (morphine hydrochloride or morphine sulfate) in 
 morphine  1 mL ampoule. 

Therapeutic alternatives: Oral liquid: 10 mg/5 mL (morphine hydrochloride or morphine 

- hydromorphone sulfate). 

- oxycodone 
Tablet (slow release): 10 mg to 200mg (morphine hydrochloride or 
morphine sulfate).  

Tablet (immediate release): 10 mg (morphine sulfate). 

Complementary list 

Tablet: 5 mg; 10 mg (hydrochloride) 

Oral liquid: 5 mg/5 mL; 10 mg/5 mL (hydrochloride) 
methadone* 

Concentrate for oral liquid: 5 mg/mL; 10 mg/mL (hydrochloride) 

*For the management of cancer pain. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 2 



WHO Model List of Essential Medicines – 23rd List (2023)  

2.3 Medicines for other common symptoms in palliative care 

amitriptyline Tablet: 10 mg; 25 mg; 75 mg.  

Injection: 50 mg/mL. 
cyclizine [c]  

Tablet: 50 mg. 

Injection: 4 mg/mL (as disodium phosphate salt) in 1 mL ampoule. 

dexamethasone  Oral liquid: 2 mg/5 mL.  

Tablet: 2 mg [c]; 4 mg. 

Injection: 5 mg/mL. 

Oral liquid: 2 mg/5 mL. 

Rectal gel: 5 mg/mL in 0.5 mL, 2 mL, 4 mL rectal delivery system. 
diazepam  

Rectal solution: 2 mg/mL in 1.25 mL, 2.5 mL rectal tube; 4 mg/mL 
in 2.5 mL rectal tube. 

Tablet: 5 mg; 10 mg. 

Capsule: 100 mg.  
docusate sodium 

Oral liquid: 50 mg/5 mL. 

fluoxetine  Solid oral dosage form: 20 mg (as hydrochloride). 

Injection: 5 mg in 1 mL ampoule. 

haloperidol Oral liquid: 2 mg/mL. 

Solid oral dosage form: 0.5 mg; 2mg; 5 mg. 

hyoscine butylbromide Injection: 20 mg/mL. 

Injection: 400 micrograms/mL; 600 micrograms/mL. 
hyoscine hydrobromide [c]  

Transdermal patches: 1 mg/72 hours. 

lactulose [c]  Oral liquid: 3.1 to 3.7 g/5 mL. 

loperamide  Solid oral dosage form: 2 mg. 

Injection: 5 mg/mL (hydrochloride) in 2 mL ampoule. 

metoclopramide Oral liquid: 5 mg/5 mL. 

Solid oral form: 10 mg (hydrochloride). 

Injection: 1 mg/mL; 5 mg/mL. 

midazolam Oral liquid: 2mg/mL [c]. 

Solid oral dosage form: 7.5 mg; 15 mg. 

 ondansetron  a Injection: 2 mg base/mL in 2 mL ampoule (as hydrochloride). 

Therapeutic alternatives: Oral liquid: 4 mg base/5 mL. 
- dolasetron Solid oral dosage form: Eq 4 mg base; Eq 8 mg base. 
- granisetron 
- palonosetron a > 1 month. 
- tropisetron 

senna Oral liquid: 7.5 mg/5 mL.  

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 3 



WHO Model List of Essential Medicines – 23rd List (2023)  

3. ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS 

dexamethasone Injection: 4 mg/mL (as disodium phosphate salt) in 1 mL ampoule. 

Injection: 1 mg/mL (as hydrochloride or hydrogen tartrate) in 1 mL 
epinephrine (adrenaline) 

ampoule. 

hydrocortisone Powder for injection: 100 mg (as sodium succinate) in vial. 

 loratadine* Oral liquid: 1 mg/mL. 

Therapeutic alternatives: Tablet: 10 mg. 

- cetirizine *There may be a role for sedating antihistamines for limited 
- fexofenadine indications (EMLc). 

 prednisolone 
Oral liquid: 5 mg/mL [c]. 

Therapeutic alternatives: 
Tablet: 5 mg; 25 mg. 

- prednisone 
 
4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS 

4.1 Non-specific 

charcoal, activated Powder. 

4.2 Specific 

Injection: 200 mg/mL in 10 mL ampoule. 
acetylcysteine 

Oral liquid: 10% [c]; 20% [c]. 

atropine Injection: 1 mg (sulfate) in 1 mL ampoule. 

calcium gluconate Injection: 100 mg/mL in 10 mL ampoule. 

methylthioninium chloride  
Injection: 10 mg/mL in 10 mL ampoule. 

(methylene blue) 

naloxone Injection: 400 micrograms (hydrochloride) in 1 mL ampoule. 

penicillamine Solid oral dosage form: 250 mg. 

potassium ferric hexacyano-ferrate(II) -2H2O 
Powder for oral administration. 

(Prussian blue) 

sodium nitrite Injection: 30 mg/mL in 10 mL ampoule. 

sodium thiosulfate Injection: 250 mg/mL in 50 mL ampoule. 

Complementary List 

deferoxamine Powder for injection: 500 mg (mesilate) in vial. 

dimercaprol Injection in oil: 50 mg/mL in 2 mL ampoule. 

Injection: 5 mg/mL (sulfate) in 20 mL ampoule or 1 g/mL (base) in 
fomepizole 

1.5 mL ampoule. 

sodium calcium edetate  Injection: 200 mg/mL in 5 mL ampoule. 

succimer Solid oral dosage form: 100 mg. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 4 



WHO Model List of Essential Medicines – 23rd List (2023)  

5. MEDICINES FOR DISEASES OF THE NERVOUS SYSTEM 

5.1 Antiseizure medicines 

Oral liquid: 100 mg/5 mL. 

carbamazepine Tablet (chewable): 100 mg; 200 mg. 

Tablet (scored): 100 mg; 200 mg; 400 mg. 

Rectal gel: 5 mg/mL in 0.5 mL, 2 mL, 4 mL rectal delivery system.  

diazepam Rectal solution: 2 mg/mL in 1.25 mL, 2.5 mL rectal tube; 4 mg/mL 
in 2.5 mL rectal tube.  

Tablet: 25 mg; 50 mg; 100 mg; 200 mg. 

Tablet (chewable, dispersible): 2 mg; 5 mg; 25 mg; 50 mg; 
lamotrigine* 100 mg; 200 mg. 

*For use as adjunctive therapy for treatment-resistant partial or 
generalized seizures. 

Oral solution: 100 mg/mL 
levetiracetam 

Tablet: 250 mg; 500 mg; 750 mg; 1000 mg. 

 lorazepam 

Therapeutic alternatives: 
Injection: 2 mg/mL in 1 mL ampoule; 4 mg/mL in 1 mL ampoule.  

- diazepam (injection) 
- midazolam (injection) 
 

Injection: 0.5 g/mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 
50% weight/volume); 0.5 g/mL in 10 mL ampoule (equivalent to 5 g 

magnesium sulfate* in 10 mL; 50% weight/volume). 

*For use in eclampsia and severe pre-eclampsia and not for other 
convulsant disorders. 

Solution for oromucosal administration: 5 mg/mL in 0.5 mL, 1 mL, 
1.5 mL, 2 mL pre-filled syringe; 10 mg/mL in 0.25 mL, 0.5 mL, 
0.75 mL, 1 mL pre-filled syringe. 

midazolam Injection*: 1 mg/mL in 5 mL vial; 5 mg/mL in 1 mL or 3 mL vial. 

*For buccal administration when solution for oromucosal 
administration is not available. 

Injection: 30 mg/mL or 60 mg/mL [c], 200 mg/mL (sodium). 

phenobarbital  Oral liquid: 15 mg/5 mL. 

Tablet: 15 mg to 100 mg. 

Injection: 50 mg/mL (phenytoin sodium). 

Oral liquid: 30 mg/5 mL (phenytoin). 
phenytoin 

Solid oral dosage form: 25 mg; 50 mg; 100 mg (phenytoin sodium). 

Tablet (chewable): 50 mg (phenytoin). 

valproic acid (sodium valproate)*  
Oral liquid: 200 mg/5 mL. 

*Avoid use in pregnancy and in women and girls of 
child-bearing potential, unless alternative treatments Tablet (crushable): 100 mg. 
are ineffective or not tolerated because of the high risk 
of birth defects and developmental disorders in Tablet (enteric-coated): 200 mg; 500 mg. 
children exposed to valproate in the womb. 

 WHO Model List of Essential Medicines – 23rd List (2023) page 5 



WHO Model List of Essential Medicines – 23rd List (2023)  

Complementary List 

Capsule: 250 mg. 
ethosuximide 

Oral liquid: 250 mg/5 mL. 

Concentrate solution for infusion: 500 mg/5mL in 5 mL vial. 

levetiracetam Solution for infusion: 5 mg/mL; 10 mg/mL; 15 mg/mL in 100 mL 
bag. 

valproic acid (sodium valproate)* 

*Avoid use in pregnancy and in women and 
girls of child-bearing potential, unless 
alternative treatments are ineffective or not Injection: 100 mg/mL in 3 mL, 4 mL, 10 mL ampoule. 

tolerated because of the high risk of birth 
defects and developmental disorders in 
children exposed to valproate in the womb. 

5.2 Medicines for multiple sclerosis 

Complementary List 

cladribine Tablet: 10 mg. 

Injection (subcutaneous): 20 mg/mL; 40 mg/mL in pre-filled 
glatiramer acetate 

syringe. 

rituximab* 
Injection (intravenous): 500 mg/50 mL in 50 mL vial. 

*including quality-assured biosimilars 

5.3 Medicines for parkinsonism 

 biperiden 
Injection: 5 mg (lactate) in 1 mL ampoule. 

Therapeutic alternatives:  
Tablet: 2 mg (hydrochloride). 

− trihexyphenidyl 

levodopa +  carbidopa  

Therapeutic alternatives:  Tablet: 100 mg + 10 mg; 100 mg + 25 mg; 250 mg + 25 mg.  

− benserazide (for carbidopa) 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 6 



WHO Model List of Essential Medicines – 23rd List (2023)  

6. ANTI-INFECTIVE MEDICINES 

6.1 Anthelminthics 

6.1.1 Intestinal anthelminthics 

albendazole Tablet (chewable, scored): 400 mg. 

ivermectin Tablet: 3 mg. 

levamisole Tablet: 50 mg; 150 mg (as hydrochloride). 

mebendazole Tablet (chewable): 100 mg; 500 mg. 

niclosamide Tablet (chewable): 500 mg. 

Tablet: 150 mg, 500 mg  
praziquantel 

Tablet (scored): 600 mg. 

pyrantel Tablet (chewable): 250 mg (as embonate or pamoate). 

6.1.2 Antifilarials 

albendazole Tablet (chewable, scored): 400 mg. 

diethylcarbamazine Tablet: 50 mg; 100 mg (dihydrogen citrate). 

ivermectin Tablet: 3 mg. 

6.1.3 Antischistosomals and other antitrematode medicines 

Tablet: 150 mg, 500 mg.  
praziquantel 

Tablet (scored): 600 mg. 

triclabendazole Tablet (scored): 250 mg. 

Complementary List 

Capsule: 250 mg. 

oxamniquine* Oral liquid: 250 mg/5 mL. 

*For use when praziquantel treatment fails. 

6.1.4 Cysticidal medicines 

Complementary List 

Tablet (chewable): 200 mg [c]. 
albendazole 

Tablet (chewable, scored): 400 mg. 

mebendazole Tablet (chewable): 100 mg [c], 500 mg. 

Tablet: 150 mg, 500 mg.  
praziquantel 

Tablet (scored): 600 mg. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 7 



WHO Model List of Essential Medicines – 23rd List (2023)  

6.2 Antibacterials 

To assist in the development of tools for antibiotic stewardship at local, national and global levels and to reduce 
antimicrobial resistance, the Access, Watch, Reserve (AWaRe) classification of antibiotics was developed – where 
antibiotics are classified into different groups to emphasize the importance of their appropriate use. 

ACCESS GROUP ANTIBIOTICS  

This group includes antibiotics that have activity against a wide range of commonly encountered susceptible pathogens 
while also showing lower resistance potential than antibiotics in the other groups. Selected Access group antibiotics are 
recommended as essential first or second choice empiric treatment options for infectious syndromes reviewed by the 
EML Expert Committee and are listed as individual medicines on the Model Lists to improve access and promote 
appropriate use. They are essential antibiotics that should be widely available, affordable and quality assured. 
 
WATCH GROUP ANTIBIOTICS  

This group includes antibiotic classes that have higher resistance potential and includes most of the highest priority agents 
among the Critically Important Antimicrobials for Human Medicine and/or antibiotics that are at relatively high risk of 
selection of bacterial resistance. These medicines should be prioritized as key targets of stewardship programs and 
monitoring. Selected Watch group antibiotics are recommended as essential first or second choice empiric treatment 
options for a limited number of specific infectious syndromes and are listed as individual medicines on the Model Lists. 

RESERVE GROUP ANTIBIOTICS  

This group includes antibiotics and antibiotic classes that should be reserved for treatment of confirmed or suspected 
infections due to multi-drug-resistant organisms. Reserve group antibiotics should be treated as “last resort” options. 
Selected Reserve group antibiotics are listed as individual medicines on the Model Lists when they have a favourable risk-
benefit profile and proven activity against “Critical Priority” or “High Priority” pathogens identified by the WHO Priority 
Pathogens List, notably carbapenem resistant Enterobacteriaceae. These antibiotics should be accessible, but their use 
should be tailored to highly specific patients and settings, when all alternatives have failed or are not suitable. These 
medicines could be protected and prioritized as key targets of national and international stewardship programs involving 
monitoring and utilization reporting, to preserve their effectiveness.  

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 8 



WHO Model List of Essential Medicines – 23rd List (2023)  

6.2.1 Access group antibiotics 

Injection: 50 mg/mL (as sulfate) [c]; 250 mg/mL (as sulfate) in 2 mL vial. 

FIRST CHOICE SECOND CHOICE 
amikacin 

− High-risk febrile neutropenia  − Sepsis in neonates and children [c] 
− Pyelonephritis or prostatitis (severe)  

Powder for injection: 250 mg; 500 mg; 1 g (as sodium) in vial. 

Powder for oral liquid: 125 mg/5 mL; 250 mg/5 mL (as trihydrate) [c]. 

Solid oral dosage form: 250 mg; 500 mg; 1g (as trihydrate). 

Tablet (dispersible, scored): 250 mg; 500 mg (as trihydrate) [c]. 

FIRST CHOICE SECOND CHOICE  

− Community acquired pneumonia − Acute bacterial meningitis 
(mild to moderate)  

amoxicillin − Community acquired pneumonia 
(severe) [c] 

 
− Complicated severe acute 

malnutrition [c] 
− Exacerbations of COPD 
− Otitis media 
− Pharyngitis 
− Progressive apical dental abscess 
− Sepsis in neonates and children [c] 
− Sinusitis 
− Uncomplicated severe acute 

malnutrition [c] 
 
Powder for injection: 500 mg (as sodium) + 100 mg (as potassium salt); 1000 mg (as 
sodium) + 200 mg (as potassium salt) in vial. 

Powder for oral liquid: 125 mg (as trihydrate)+ 31.25 mg (as potassium salt)/5 mL; 
250 mg (as trihydrate) + 62.5 mg (as potassium salt)/5mL [c]. 

Tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) 
+ 125 mg (as potassium salt). 

Tablet (dispersible): 200 mg (as trihydrate) + 28.5 mg (as potassium salt) [c]; 
250 mg (as trihydrate) + 62.5 mg (as potassium salt) [c]. 

amoxicillin + clavulanic acid  SECOND CHOICE 
FIRST CHOICE 

 − Bone and joint infections 
− Community acquired pneumonia 

− Community-acquired pneumonia (mild to 
(severe) [c] moderate)  

− Complicated intraabdominal 
− Community acquired pneumonia 

infections (mild to moderate) (severe) 
− Exacerbations of COPD − Otitis media 
− Hospital acquired pneumonia 

− Surgical prophylaxis 
− Low-risk febrile neutropenia 
− Lower urinary tract infections  
− Sinusitis 
− Skin and soft tissue infections  

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 9 



WHO Model List of Essential Medicines – 23rd List (2023)  

Powder for injection: 500 mg; 1 g (as sodium) in vial. 

FIRST CHOICE SECOND CHOICE 

− Community acquired pneumonia − Acute bacterial meningitis 
(severe) [c]  

ampicillin 
− Complicated intraabdominal  

infections [c] 
− Complicated severe acute 

malnutrition [c] 
− Sepsis in neonates and children [c] 
 

Powder for injection: 1.2 million IU (≈ 900 mg) in vial [c]; 2.4 million IU (≈ 1.8 g) in 
vial. 

benzathine benzylpenicillin 

 FIRST CHOICE SECOND CHOICE 

− Syphilis 

Powder for injection: 600 mg (= 1 million IU); 3 g (= 5 million IU) (sodium or 
potassium salt) in vial. 

FIRST CHOICE SECOND CHOICE 

benzylpenicillin − Acute bacterial meningitis 
− Community acquired pneumonia 

 
(severe) [c] 

  
− Complicated severe acute 

malnutrition [c] 
− Sepsis in neonates and children [c] 
− Syphilis 
 
Powder for oral liquid: 125 mg/5 mL; 250 mg/5 mL (anhydrous).  

Solid oral dosage form: 250 mg; 500 mg (as monohydrate). 

cefalexin  Tablet (dispersible): 125 mg [c]; 250 mg [c]. 

FIRST CHOICE SECOND CHOICE 

− Skin and soft tissue infections  − Exacerbations of COPD 
 − Pharyngitis 

Powder for injection: 1 g (as sodium salt) in vial. 

a > 1 month. 

cefazolin a 
FIRST CHOICE SECOND CHOICE 

− Surgical prophylaxis − Bone and joint infections 
 

Oily suspension for injection*: 0.5 g/mL (as sodium succinate) in 2 mL ampoule. 

*Only for the presumptive treatment of epidemic meningitis in children older than 2 
years and in adults. 

chloramphenicol Powder for injection: 1 g (as sodium succinate) in vial. 

FIRST CHOICE SECOND CHOICE 

− Acute bacterial meningitis 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 10 



WHO Model List of Essential Medicines – 23rd List (2023)  

Capsule: 150 mg (as hydrochloride). 

Injection: 150 mg/mL (as phosphate); 600 mg/4 mL (as phosphate); 900 mg/6 mL 
(as phosphate). 

clindamycin 
Powder for oral liquid: 75 mg/5 mL (as palmitate hydrochloride) [c]. 

FIRST CHOICE SECOND CHOICE 

− Necrotizing fasciitis − Bone and joint infections 

Capsule: 250 mg [c], 500 mg; 1 g (as sodium). 

Powder for injection: 250 mg [c], 500 mg (as sodium) in vial. 

 cloxacillin* Powder for oral liquid: 125 mg/5 mL, 250 mg/5 mL (as sodium) [c]. 
Therapeutic alternatives: 

*cloxacillin, dicloxacillin and flucloxacillin are preferred for oral administration due to 
- 4th level ATC chemical subgroup better bioavailability. 
(J01CF Beta-lactamase resistant 
penicillins) FIRST CHOICE SECOND CHOICE 

− Bone and joint infections  − Sepsis in neonates and children [c] 
− Skin and soft tissue infections  

 
 
Oral liquid: 50 mg/5 mL (calcium) [c]. 

Powder for oral liquid: 25 mg/5 mL (monohydrate) [c]. 

Powder for injection: 100 mg in vial. 

Solid oral dosage form: 50 mg [c]; 100 mg (as hyclate).  

Tablet (dispersible): 100 mg (as monohydrate) [c]. 
doxycycline a 

a Use in children <8 years only for life-threatening infections when no alternative exists. 

FIRST CHOICE SECOND CHOICE 

− Cholera  − Cholera [c] 
− Sexually transmitted infection due to − Community acquired pneumonia (mild to 

Chlamydia trachomatis moderate)  
− Exacerbations of COPD 
 

Injection: 10 mg/mL (as sulfate); 40 mg/mL (as sulfate) in 2 mL vial. 

FIRST CHOICE SECOND CHOICE 

− Acute bacterial meningitis in − Gonorrhoea 
neonates [c] − Surgical prophylaxis 

− Community acquired pneumonia 
gentamicin 

(severe) [c] 
− Complicated intraabdominal 

infections [c] 
− Complicated severe acute 

malnutrition [c] 
− Sepsis in neonates and children [c] 
 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 11 



WHO Model List of Essential Medicines – 23rd List (2023)  

Injection: 500 mg in 100 mL vial. 

Oral liquid: 200 mg/5 mL (as benzoate). 

Suppository: 500 mg; 1 g. 

Tablet: 200 mg; 250 mg; 400 mg; 500 mg. 

FIRST CHOICE SECOND CHOICE 

metronidazole  − C. difficile infection − Complicated intraabdominal infections 
− Complicated intraabdominal (mild to moderate) 

infections (mild to moderate)  
− Complicated intrabdominal 

infections (severe) 
− Necrotizing fasciitis 
− Surgical prophylaxis 
− Trichomoniasis 
 
Oral liquid: 25 mg/5 mL [c]. 

Solid oral dosage form: 50 mg [c]; 100 mg. 
nitrofurantoin 

FIRST CHOICE SECOND CHOICE 

− Lower urinary tract infections 

Powder for oral liquid: 250 mg/5 mL (as potassium). 

Solid oral dosage form: 250 mg; 500 mg (as potassium). 

SECOND CHOICE 
FIRST CHOICE 

phenoxymethylpenicillin 

− Community acquired pneumonia 
(mild to moderate) 

− Pharyngitis 
− Progressive apical dental abscess 

Powder for injection: 1 g (=1 million IU); 3 g (=3 million IU) in vial.  

*Procaine benzylpenicillin is not recommended as first-line treatment for neonatal 
sepsis except in settings with high neonatal mortality, when given by trained health 

procaine benzylpenicillin* workers in cases where hospital care is not achievable. 

FIRST CHOICE SECOND CHOICE 

− Syphilis (congenital) [c] − Syphilis  

Powder for injection: 2 g (as hydrochloride) in vial. 

spectinomycin FIRST CHOICE SECOND CHOICE 

− Gonorrhoea 
 

Injection: 80 mg + 16 mg/mL in 5 mL ampoule; 80 mg + 16 mg/mL in 10 mL 
ampoule. 

Oral liquid: 200 mg + 40 mg/5 mL. 

Tablet: 100 mg + 20 mg; 400 mg + 80 mg; 800 mg + 160 mg. 
sulfamethoxazole + 
trimethoprim  Tablet (dispersible): 100 mg + 20 mg [c]. 

FIRST CHOICE SECOND CHOICE 

− Lower urinary tract infections − Acute invasive diarrhoea / bacterial 
 dysentery  

 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 12 



WHO Model List of Essential Medicines – 23rd List (2023)  

Tablet: 100 mg; 200 mg. 

Oral liquid: 50 mg/5 mL [c]. 

trimethoprim 
FIRST CHOICE SECOND CHOICE 

− Lower urinary tract infections 
 

6.2.2 Watch group antibiotics 

Solid oral dosage form: 250 mg; 500 mg (anhydrous). 

Powder for oral liquid: 200 mg/5 mL (anhydrous) [c]. 

FIRST CHOICE 

azithromycin − Cholera 
SECOND CHOICE 

 − Enteric fever 
− Gonorrhoea − Acute invasive bacterial diarrhoea / 
− Sexually transmitted infection due to dysentery  

Chlamydia trachomatis − Gonorrhoea 
− Trachoma  
− Yaws 
 
Powder for oral liquid: 100 mg/5 mL [c]. 

Solid oral dosage form: 200 mg; 400 mg (as trihydrate). 

cefixime 
FIRST CHOICE SECOND CHOICE 

 
 − Acute invasive bacterial diarrhoea / 

dysentery  
− Gonorrhoea 
 

Powder for injection: 250 mg; 500 mg; 1 g; 2 g (as sodium) in vial. 

*3rd generation cephalosporin of choice for use in hospitalized neonates. 

FIRST CHOICE SECOND CHOICE 

− Acute bacterial meningitis − Bone and joint infections 
cefotaxime*  − Community acquired pneumonia − Pyelonephritis or prostatitis (mild to 

(severe)  moderate) 
 

− Complicated intraabdominal − Sepsis in neonates and children [c] 
infections (mild to moderate)  

− Complicated intraabdominal 
infections (severe) 

− Hospital acquired pneumonia 
− Pyelonephritis or prostatitis (severe)  

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 13 



WHO Model List of Essential Medicines – 23rd List (2023)  

Powder for injection: 250 mg; 500 mg; 1 g; 2 g (as sodium) in vial. 

*Do not administer with calcium and avoid in infants with hyperbilirubinaemia. 

a > 41 weeks corrected gestational age. 

FIRST CHOICE SECOND CHOICE 

− Acute bacterial meningitis − Acute invasive bacterial diarrhoea / 
− Community acquired pneumonia dysentery  

(severe)  − Bone and joint infections 
ceftriaxone* a  

− Complicated intraabdominal − Pyelonephritis or prostatitis (mild to 
 infections (mild to moderate) moderate) 

− Complicated intrabdominal − Sepsis in neonates and children [c] 
infections (severe)  

− Endophthalmitis   
− Enteric fever  
− Gonorrhoea 
− Hospital acquired pneumonia 
− Necrotizing fasciitis 
− Pyelonephritis or prostatitis (severe)  
 

Powder for injection: 250 mg; 750 mg; 1.5 g (as sodium) in vial. 

cefuroxime FIRST CHOICE SECOND CHOICE 

 − Surgical prophylaxis 
 

Oral liquid: 250 mg/5 mL (anhydrous) [c]. 

Solution for IV infusion: 2 mg/mL (as hyclate) [c]. 

Solid oral dosage form: 100 mg [c]; 250 mg; 500 mg (as hydrochloride). 

ciprofloxacin FIRST CHOICE SECOND CHOICE 

− Acute invasive bacterial diarrhoea / − Cholera  
 

dysentery  − Complicated intraabdominal infections 
− Enteric fever (mild to moderate) 
− Low-risk febrile neutropenia  
− Pyelonephritis or prostatitis (mild to 

moderate) 
 
Powder for oral liquid: 125 mg/5 mL; 250 mg/5 mL. 

Powder for injection: 500 mg in vial. 
 clarithromycin†  

Solid oral dosage form: 250 mg [c]; 500 mg. 
Therapeutic alternatives: 

- erythromycin* †clarithromycin is also listed for use in combination regimens for eradication of H. pylori in 
adults. 

*as second choice treatment for 
pharyngitis in children (EMLc only) FIRST CHOICE SECOND CHOICE 

Community acquired pneumonia − Pharyngitis 
(severe)  

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 14 



WHO Model List of Essential Medicines – 23rd List (2023)  

Powder for injection: 2 g (as sodium) + 250 mg (as sodium); 4 g (as sodium) + 
500 mg (as sodium) in vial. 

FIRST CHOICE SECOND CHOICE 
piperacillin + tazobactam 

− Complicated intraabdominal  
 infections (severe) 

− High-risk febrile neutropenia 
− Hospital acquired pneumonia 
− Necrotizing fasciitis 
 
Capsule: 125 mg; 250 mg (as hydrochloride). 

*vancomycin powder for injection may also be used for oral administration 
vancomycin* 

FIRST CHOICE 
SECOND CHOICE 

− C. difficile infection 

Complementary List 

Powder for injection: 250 mg; 1 g (as pentahydrate) in vial. 

ceftazidime FIRST CHOICE SECOND CHOICE 

− Endophthalmitis   

 meropenem* a Powder for injection: 500 mg (as trihydrate); 1 g (as trihydrate) in vial. 

 a > 3 months. 

Therapeutic alternatives*: 
FIRST CHOICE SECOND CHOICE 

- imipenem + cilastatin 
  − Acute bacterial meningitis in neonates 
*complicated intraabdominal 

[c]  
infections and high-risk febrile 

− Complicated intraabdominal infections 
neutropenia only. Meropenem is 
the preferred choice for acute (severe) 

bacterial meningitis in neonates. − High-risk febrile neutropenia 
  

Powder for injection: 250 mg; 500 mg; 1 g (as hydrochloride) in vial. 

FIRST CHOICE 
vancomycin SECOND CHOICE 

− Endophthalmitis  
− High-risk febrile neutropenia 

− Necrotizing fasciitis 
 

 
6.2.3 Reserve group antibiotics 

Complementary List  

cefiderocol Powder for injection: 1 g (as sulfate toxylate) in vial. 

ceftazidime + avibactam Powder for injection: 2 g + 0.5 g in vial. 

ceftolozane + tazobactam Powder for injection: 1 g + 0.5 g in vial. 

Powder for injection: 1 million IU (as colistemethate sodium) (equivalent 
colistin  

to 34 mg colistin base activity) in vial. 

fosfomycin Powder for injection: 2 g; 4 g (as sodium) in vial. 

Injection for intravenous administration: 2 mg/mL in 300 mL bag. 
o linezolid 

Powder for oral liquid: 100 mg/5 mL. 
Therapeutic alternatives: 

Tablet: 600 mg. 
- tedizolid phosphate 

Tablet (dispersible): 150 mg [c]. 

 WHO Model List of Essential Medicines – 23rd List (2023) page 15 



WHO Model List of Essential Medicines – 23rd List (2023)  

meropenem + vaborbactam Powder for injection: 1 g (as trihydrate) + 1 g in vial. 

plazomicin Injection: 500 mg/10 mL. 

Powder for injection: 500 000 IU (equivalent to 50 mg polymyxin B 
polymyxin B 

base) in vial. 
6.2.4 Antileprosy medicines 

Medicines used in the treatment of leprosy should never be used except in combination. Combination therapy is essential to prevent 
the emergence of drug resistance. Colour-coded blister packs (MDT blister packs) containing standard two-medicine (paucibacillary 
leprosy) or three-medicine (multibacillary leprosy) combinations for adult and childhood leprosy should be used. MDT blister packs can 
be supplied free of charge through WHO. 

clofazimine Solid oral dosage form: 50 mg; 100 mg. 

dapsone Tablet: 25 mg; 50 mg; 100 mg. 

Oral liquid: 20 mg/mL [c]. 
rifampicin 

Solid oral dosage form: 150 mg; 300 mg. 

6.2.5 Antituberculosis medicines 

WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new fixed-dose 
combinations, including modified dosage forms, non-refrigerated products and paediatric dosage forms of assured pharmaceutical 
quality.  

Tablet: 100 mg; 400 mg (hydrochloride). 
ethambutol 

Tablet (dispersible): 100 mg [c] 

ethambutol + isoniazid + pyrazinamide + 
Tablet: 275 mg + 75 mg + 400 mg + 150 mg. 

rifampicin  

ethambutol + isoniazid + rifampicin Tablet: 275 mg + 75 mg + 150 mg. 

Tablet: 250 mg. 
ethionamide 

Tablet (dispersible): 125 mg [c]. 

Tablet: 100 mg; 300 mg. 
isoniazid 

Tablet (dispersible): 100 mg [c]. 

isoniazid + pyrazinamide + rifampicin  Tablet (dispersible): 50 mg + 150 mg + 75 mg [c].  

Tablet: 75 mg + 150 mg; 150 mg + 300 mg. 
isoniazid + rifampicin  

Tablet (dispersible): 50 mg + 75 mg [c].  

isoniazid + rifapentine Tablet (scored): 300 mg + 300 mg. 

moxifloxacin Tablet: 400 mg. 

Tablet: 400 mg; 500 mg 
pyrazinamide 

Tablet (dispersible): 150 mg. 

Solid oral dosage form: 150 mg.* 
rifabutin 

*For use only in patients with HIV receiving protease inhibitors.  

Oral liquid: 20 mg/mL [c]. 
rifampicin 

Solid oral dosage form: 150 mg; 300 mg. 

rifapentine Tablet: 150 mg; 300 mg. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 16 



WHO Model List of Essential Medicines – 23rd List (2023)  

Complementary List 

Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO 
standards for TB control.  

amikacin Injection: 250 mg/mL (as sulfate) in 2 mL vial. 

Powder for oral liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium 
salt)/5mL [c]. 

amoxicillin + clavulanic acid* 
Tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt). 

*For use only in combination with meropenem or imipenem+cilastatin. 

bedaquiline  Tablet: 20 mg [c]; 100 mg. 

clofazimine Solid oral dosage form: 50 mg; 100 mg. 

 cycloserine 

Therapeutic alternatives: Solid oral dosage form: 125 mg [c]; 250 mg. 

- terizidone 

Tablet (dispersible): 25 mg [c]. 
delamanid 

Tablet: 50 mg. 
 ethionamide 

Tablet: 250 mg. 
Therapeutic alternatives: 

Tablet (dispersible): 125 mg [c]. 
- protionamide 

Tablet: 250mg; 500 mg; 750 mg. 
levofloxacin 

Tablet (dispersible): 100 mg [c]. 

Tablet: 600 mg. 
linezolid 

Tablet (dispersible): 150 mg [c]. 

 meropenem 

Therapeutic alternatives: Powder for injection: 500 mg (as trihydrate); 1 g (as trihydrate) in vial. 

- imipenem + cilastatin 

Tablet: 400 mg. 
moxifloxacin 

Tablet (dispersible): 100 mg [c]. 

Powder for oral solution: 5.52 g in sachet (equivalent to 4 g 
p-aminosalicylate sodium 

p-aminosalicylic acid). 

pretomanid Tablet: 200 mg. 

streptomycin [c] Powder for injection: 1 g (as sulfate) in vial. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 17 



WHO Model List of Essential Medicines – 23rd List (2023)  

 
6.3 Antifungal medicines 

Powder for injection: 50 mg (liposomal complex) in vial. 

Powder for injection: 50 mg (as sodium deoxycholate) in vial 
amphotericin B* 

*Liposomal amphotericin B has a better safety profile than the sodium 
deoxycholate formulation and should be prioritized for selection and use 
depending on local availability and cost. 

Vaginal cream: 1%; 10%. 
clotrimazole 

Vaginal tablet: 100 mg; 500 mg. 

Capsule: 50 mg. 

Injection: 2 mg/mL in vial. 
fluconazole 

Oral liquid: 50 mg/5 mL. 

Powder for oral liquid: 50 mg/5 mL [c]. 

Capsule: 250 mg. 
flucytosine 

Infusion: 2.5 g in 250 mL. 

Oral liquid: 125 mg/5 mL [c]. 
griseofulvin 

Solid oral dosage form: 125 mg; 250 mg. 

Capsule: 100 mg. 

Oral liquid: 10 mg/mL. 

itraconazole* *For treatment of chronic pulmonary aspergillosis, histoplasmosis, 
sporotrichosis, paracoccidiodomycosis, mycoses caused by T. 
marneffei and chromoblastomycosis; and prophylaxis of 
histoplasmosis and infections caused by T. marneffei in AIDS patients. 

Lozenge: 100 000 IU. 

Oral liquid: 100 000 IU/mL [c]. 
nystatin 

Pessary: 100 000 IU. 

Solid oral dosage form: 500 000 IU. 

Tablet: 50 mg; 200 mg 

Powder for injection: 200 mg in vial 

voriconazole* Powder for oral liquid: 40 mg/mL 

*For treatment of chronic pulmonary aspergillosis and acute invasive 
aspergillosis. 

Complementary List 

 micafungin 

Therapeutic alternatives:  Powder for injection: 50 mg (as sodium); 100 mg (as sodium) in vial. 

- anidulafungin 
- caspofungin 

potassium iodide Saturated solution. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 18 



WHO Model List of Essential Medicines – 23rd List (2023)  

6.4 Antiviral medicines 

6.4.1 Antiherpes medicines 

 aciclovir Oral liquid: 200 mg/5 mL [c]. 

Therapeutic alternatives: Powder for injection: 250 mg (as sodium salt) in vial. 

- valaciclovir (oral) Tablet: 200 mg. 

6.4.2 Antiretrovirals 

Based on current evidence and experience of use, medicines in the following classes of antiretrovirals are included as essential 
medicines for treatment and prevention of HIV (prevention of mother-to-child transmission, pre-exposure prophylaxsis (where 
indicated) and post-exposure prophylaxis). WHO emphasizes the importance of using these products in accordance with global and 
national guidelines. WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new 
fixed-dose combinations, including modified dosage forms, non-refrigerated products and paediatric dosage forms of assured 
pharmaceutical quality. 

Scored tablets can be used in children and therefore can be considered for inclusion in the listing of tablets, provided that adequate 
quality products are available. 

6.4.2.1 Nucleoside/Nucleotide reverse transcriptase inhibitors 

abacavir Tablet: 300 mg (as sulfate). 

Oral liquid: 50 mg/5 mL [c]. 
lamivudine 

Tablet: 150 mg. 

Tablet: 300 mg (tenofovir disoproxil fumarate – equivalent to 

tenofovir disoproxil fumarate†  245 mg tenofovir disoproxil). 

†also indicated for pre-exposure prophylaxis. 

Capsule: 250 mg. 

Oral liquid: 50 mg/5 mL. 
zidovudine 

Solution for IV infusion: 10 mg/mL in 20 mL vial. 

Tablet: 300 mg. 

6.4.2.2 Non-nucleoside reverse transcriptase inhibitors 

efavirenz Tablet: 600 mg. 

Oral liquid: 50 mg/5 mL. 

nevirapine a  Tablet: 50 mg (dispersible); 200 mg. 

a > 6 weeks 

6.4.2.3 Protease inhibitors 

Selection of protease inhibitor(s) from the Model List will need to be determined by each country after consideration of international 
and national treatment guidelines and experience. Ritonavir is recommended for use in combination as a pharmacological booster, and 
not as an antiretroviral in its own right. All other protease inhibitors should be used in boosted forms (e.g. with ritonavir). 

atazanavir + ritonavir  Tablet (heat stable): 300 mg (as sulfate) + 100 mg. 

Tablet: 75 mg; 400 mg; 600 mg; 800 mg 
darunavira 

a > 3 years 

Solid oral dosage form: 40 mg + 10 mg [c]. 
lopinavir + ritonavir  

Tablet (heat stable): 100 mg + 25 mg; 200 mg + 50 mg. 

ritonavir Tablet (heat stable): 25 mg; 100 mg.  

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 19 



WHO Model List of Essential Medicines – 23rd List (2023)  

6.4.2.4 Integrase inhibitors 

Tablet (dispersible, scored): 10 mg [c]. 

a ≥ 4 weeks and ≥ 3 kg 
dolutegravir a  

Tablet: 50 mg  

a ≥ 25 kg  

Granules for oral suspension: 100 mg in sachet. 

Tablet (chewable): 25 mg. 

raltegravir* Tablet: 400 mg. 

*For use in pregnant women and in second-line regimens in 
accordance with WHO treatemnt guidelines. 

6.4.2.5 Fixed-dose combinations of antiretroviral medicines 

abacavir + lamivudine Tablet (dispersible, scored): 120 mg (as sulfate) + 60 mg. 

Tablet: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate – 
dolutegravir + lamivudine + tenofovir 

equivalent to 245 mg tenofovir disoproxil) 

efavirenz +  emtricitabine + tenofovir  
Tablet: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate 

Therapeutic alternatives: 
– equivalent to 245 mg tenofovir disoproxil). 

- lamivudine (for emtricitabine) 

Tablet: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate 
efavirenz + lamivudine + tenofovir 

– equivalent to 245 mg tenofovir disoproxil) 

 emtricitabine + tenofovir†  Tablet: 200 mg + 300 mg (tenofovir disoproxil fumarate – 

Therapeutic alternatives: equivalent to 245 mg tenofovir disoproxil). 

- lamivudine (for emtricitabine) † combination also indicated for pre-exposure prophylaxis 

lamivudine + zidovudine Tablet: 30 mg + 60 mg [c]; 150 mg + 300 mg. 

6.4.2.6 Medicines for prevention of HIV-related opportunistic infections 

isoniazid + pyridoxine + sulfamethoxazole + 
Tablet (scored): 300 mg + 25 mg + 800 mg + 160 mg 

trimethoprim 

6.4.3 Other antivirals 

Injection for intravenous administration: 800 mg and 1 g in 10 mL 
phosphate buffer solution. 

ribavirin* 
Solid oral dosage form: 200 mg; 400 mg; 600 mg. 

*For the treatment of viral haemorrhagic fevers  

Tablet: 450 mg. 
valganciclovir* 

*For the treatment of cytomegalovirus retinitis (CMVr). 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 20 



WHO Model List of Essential Medicines – 23rd List (2023)  

Complementary list 

Capsule: 30 mg; 45 mg; 75 mg (as phosphate). 

oseltamivir* *Severe illness due to confirmed or suspected influenza virus 
infection in critically ill hospitalized patients 

Powder for oral solution: 50 mg/mL 

valganciclovir*[c] Tablet: 450 mg. 

*For the treatment of cytomegalovirus retinitis (CMVr). 

6.4.4 Antihepatitis medicines 

6.4.4.1 Medicines for hepatitis B 

6.4.4.1.1 Nucleoside/Nucleotide reverse transcriptase inhibitors 

Oral liquid: 0.05 mg/mL 

entecavir 
Tablet: 0.5 mg; 1 mg 

Tablet: 300 mg (tenofovir disoproxil fumarate – equivalent to 
tenofovir disoproxil fumarate  

245 mg tenofovir disoproxil). 

6.4.4.2 Medicines for hepatitis C  

Pangenotypic direct-acting antivirals should be considered as therapeutic alternatives for the purposes of selection and procurement 
at national level. 

6.4.4.2.1 □ Pangenotypic direct-acting antiviral combinations 

Tablet: 30 mg; 60 mg (as hydrochloride). 
daclatasvir* 

*Pangenotypic when used in combination with sofosbuvir 

daclatasvir + sofosbuvir  Tablet: 60 mg + 400 mg. 

Tablet: 100 mg + 40 mg. 
glecaprevir + pibrentasvir 

Granules: 50 mg + 20 mg in sachet [c]. 

Tablet: 200 mg. 
ravidasvir* 

*Pangenotypic when used in combination with sofosbuvir 

Tablet: 200 mg; 400 mg. 

sofosbuvir*  *Pangenotypic when used in combination with daclatasvir or 
ravidasvir 

sofosbuvir + velpatasvir Tablet: 200 mg + 50 mg [c]; 400 mg + 100 mg. 

6.4.4.2.2 Non-pangenotypic direct-acting antiviral combinations 

ledipasvir + sofosbuvir  Tablet: 90 mg + 400 mg. 

6.4.4.2.3 Other antivirals for hepatitis C 

Injection for intravenous administration: 800 mg and 1 g in 10 mL 
phosphate buffer solution. 

ribavirin* Solid oral dosage form: 200 mg; 400 mg; 600 mg. 

*For the treatment of hepatitis C, in combination with direct acting 
anti-viral medicines 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 21 



WHO Model List of Essential Medicines – 23rd List (2023)  

6.5 Antiprotozoal medicines 

6.5.1 Antiamoebic and antigiardiasis medicines 

Tablet: 500 mg (furoate). 
diloxanide a  

a > 25 kg. 

 metronidazole Injection: 500 mg in 100 mL vial. 

Therapeutic alternatives: Oral liquid: 200 mg/5 mL (as benzoate). 

- tinidazole Tablet: 200 mg; 250 mg; 400 mg; 500 mg. 

6.5.2 Antileishmaniasis medicines 

Powder for injection: 50 mg (liposomal complex) in vial. 

Powder for injection: 50 mg (as sodium deoxycholate) in vial. 
amphotericin B* 

*Liposomal amphotericin B has a better safety profile than the sodium 
deoxycholate formulation and should be prioritized for selection and use 
depending on local availability and cost. 

meglumine antimoniate Injection: 1.5 g/5 mL in 5 mL ampoule. 

miltefosine Solid oral dosage form: 10 mg; 50 mg. 

paromomycin Solution for intramuscular injection: 750 mg of paromomycin base 
(as sulfate). 

sodium stibogluconate  Injection: 100 mg/mL in 30 mL vial.  

6.5.3 Antimalarial medicines 

6.5.3.1 For curative treatment 

Medicines for the treatment of P. falciparum malaria cases should be used in combination. The list currently recommends combinations 
according to treatment guidelines. WHO recognizes that not all of the fixed dose combinations (FDCs) in the WHO treatment guidelines 
exist, and encourages their development and rigorous testing. WHO also encourages development and testing of rectal dosage 
formulations. 

Tablet: 153 mg or 200 mg (as hydrochloride). 
amodiaquine* 

*To be used in combination with artesunate 50 mg. 

Oily injection: 80 mg/mL in 1 mL ampoule. 
artemether* 

*For use in the management of severe malaria. 

Tablet: 20 mg + 120 mg. 

Tablet (dispersible): 20 mg + 120 mg [c]. 
artemether + lumefantrine* 

*Not recommended in the first trimester of pregnancy or in 
children below 5 kg. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 22 



WHO Model List of Essential Medicines – 23rd List (2023)  

Injection: ampoules, containing 60 mg anhydrous artesunic acid 
with a separate ampoule of 5% sodium bicarbonate solution. 
For use in the management of severe malaria. 

Rectal dosage form: 50 mg [c]; 100 mg [c]; 200 mg capsules (for 

artesunate* pre-referral treatment of severe malaria only; patients should be 
taken to an appropriate health facility for follow-up care) [c]. 

Tablet: 50 mg. 

*To be used in combination with either amodiaquine, mefloquine 
or sulfadoxine + pyrimethamine. 

Tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg. 

artesunate + amodiaquine* *Other combinations that deliver the target doses required such 
as 153 mg or 200 mg (as hydrochloride) with 50 mg artesunate 
can be alternatives. 

artesunate + mefloquine Tablet: 25 mg + 55 mg; 100 mg + 220 mg. 

Granules: 20 mg + 60 mg [c]. 

artesunate + pyronaridine tetraphosphate a  Tablet: 60 mg + 180 mg. 

a > 5 kg 

Oral liquid: 50 mg/5 mL (as phosphate or sulfate). 

chloroquine* Tablet: 100 mg; 150 mg (as phosphate or sulfate). 

*For use only for the treatment of Plasmodium vivax infection. 

Tablet: 20 mg + 160 mg; 40 mg + 320 mg. 
dihydroartemisinin + piperaquine phosphate a  

a > 5 kg 

Capsule: 100 mg (as hydrochloride or hyclate). 

doxycycline* Tablet (dispersible): 100 mg (as monohydrate). 

*For use only in combination with quinine. 

Tablet: 250 mg (as hydrochloride).  
mefloquine* 

*To be used in combination with artesunate 50 mg. 

Tablet: 7.5 mg; 15 mg (as diphosphate). 

primaquine* *Only for use to achieve radical cure of Plasmodium vivax and 
Plasmodium ovale infections, given for 14 days. 

Injection: 300 mg/mL (hydrochloride) in 2 mL ampoule. 

Tablet: 300 mg (sulfate) or 300 mg (bisulfate). 
quinine* 

*For use only in the management of severe malaria and should be 
used in combination with doxycycline. 

Tablet: 500 mg + 25 mg. 
sulfadoxine + pyrimethamine* 

*Only in combination with artesunate 50 mg. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 23 



WHO Model List of Essential Medicines – 23rd List (2023)  

6.5.3.2 For chemoprevention 

Co-packaged dispersible tablets:  

amodiaquine 76.5 mg (as hydrochloride) [3] and sulfadoxine + 
amodiaquine – sulfadoxine + pyrimethamine [c] pyrimethamine 250 mg + 12.5 mg [1];  

amodiaquine 153 mg (as hydrochloride) [3] and sulfadoxine 
+ pyrimethamine 500 mg + 25 mg [1]. 

Oral liquid: 50 mg/5 mL (as phosphate or sulfate). 

Tablet: 150 mg (as phosphate or sulfate). 
chloroquine* 

*For use only in central American regions, for Plasmodium vivax 
infections. 

Solid oral dosage form: 100 mg (as hydrochloride or hyclate). 
doxycycline a  

a > 8 years. 

Tablet: 250 mg (as hydrochloride). 
mefloquine a  

a > 5 kg or > 3 months. 

Tablet: 100 mg (as hydrochloride). 
proguanil* 

*For use only in combination with chloroquine. 

sulfadoxine + pyrimethamine Tablet: 250 mg + 12.5 mg [c]; 500 mg + 25 mg.  

6.5.4 Antipneumocystosis and antitoxoplasmosis medicines 

pyrimethamine Tablet: 25 mg. 

sulfadiazine Tablet: 500 mg. 

Injection: 80 mg + 16 mg/mL in 5 mL ampoule; 80 mg + 
16 mg/mL in 10 mL ampoule. 

sulfamethoxazole + trimethoprim Oral liquid: 200 mg + 40 mg/5 mL [c]. 

Tablet: 100 mg + 20 mg; 400 mg + 80 mg [c]; 800 mg + 160 mg. 

Tablet (dispersible): 100 mg + 20 mg [c]. 

Complementary List 

pentamidine Tablet: 200 mg; 300 mg (as isethionate). 

6.5.5 Antitrypanosomal medicines 

6.5.5.1 African trypanosomiasis 

Tablet: 600 mg 
fexinidazole* *For the treatment of 1st and 2nd stage of human African 

trypanosomiasis due to Trypanosoma brucei gambiense infection. 
Medicines for the treatment of 1st stage African trypanosomiasis 

Powder for injection: 300 mg (as isetionate) in vial. 

pentamidine* *To be used for the treatment of Trypanosoma brucei gambiense 
infection. 

Powder for injection: 1 g in vial. 

suramin sodium* *To be used for the treatment of the initial phase of Trypanosoma 
brucei rhodesiense infection. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 24 



WHO Model List of Essential Medicines – 23rd List (2023)  

Medicines for the treatment of 2nd stage African trypanosomiasis 

Injection: 200 mg/mL (hydrochloride) in 50 mL bottle. 

eflornithine* *To be used for the treatment of Trypanosoma brucei gambiense 
infection. 

melarsoprol Injection: 180 mg/5 mL in 5 mL ampoule (3.6% solution). 

Tablet (scored): 30 mg; 120 mg. 

nifurtimox * *Only to be used in combination with eflornithine, for the 
treatment of Trypanosoma brucei gambiense infection. 

Complementary List  

melarsoprol [c] Injection: 180 mg/5 mL in 5 mL ampoule (3.6% solution). 

6.5.5.2 American trypanosomiasis 

Tablet: 12.5 mg [c] 
benznidazole 

Tablet (scored): 50 mg; 100 mg. 

nifurtimox Tablet (scored): 30 mg; 120 mg. 

6.6 Medicines for ectoparasitic infections 

ivermectin Tablet: 3 mg 

6.7 Medicines for Ebola virus disease 

ansuvimab Powder for injection: 400 mg 

atoltivimab + maftivimab + odesivimab Injection: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial  

6.8 Medicines for COVID-19 

WHO recommends that effective and safe therapeutics for prevention and treatment of COVID-19 should be considered as essential 
medicines in the context of the public health emergency. WHO recommendations are revised and updated regularly in WHO living 
guidelines for therapeutics for the treatment and prevention of COVID-19. 

Selection of essential therapeutics for COVID-19 at the national level should be informed by recommendations in these guidelines, 
and consideration of the latest evidence, epidemiology and national priorities. 

The latest WHO Therapeutics and COVID-19: living guideline is available online at: https://app.magicapp.org/#/guideline/nBkO1E  

The latest WHO Drugs to prevent COVID-19: living guideline is available online at: https://app.magicapp.org/#/guideline/L6RxYL  

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 25 



WHO Model List of Essential Medicines – 23rd List (2023)  

7. ANTIMIGRAINE MEDICINES 

7.1 For treatment of acute attack 

acetylsalicylic acid Tablet: 300 mg to 500 mg. 

Oral liquid: 100 mg/5 mL [c]. 
ibuprofen [c] 

Tablet: 200 mg; 400 mg. 

Oral liquid: 120 mg/5 mL or 125 mg/5 mL*; 250 mg/5 mL [c]. 

*The presence of both 120 mg/5 mL and 125 mg/5mL strengths on the 
same market would cause confusion in prescribing and dispensing and 
should be avoided. 

paracetamol (acetaminophen) 
Suppository: 250 mg [c]. 

Tablet: 250 mg; 325 mg; 500 mg. 

Tablet (dispersible): 100 mg, 250 mg [c]. 

sumatriptan Tablet: 50 mg 

7.2 For prophylaxis 

 propranolol 
Tablet: 20 mg; 40 mg (hydrochloride). 

Therapeutic alternatives to be reviewed 
 

8. IMMUNOMODULATORS AND ANTINEOPLASTICS  

8.1 Immunomodulators for non-malignant disease 

 Complementary List 

 adalimumab* 

Therapeutic alternatives*:  

- certolizumab pegol Injection: 10 mg/0.2 mL [c]; 20 mg/0.4 mL [c]; 40 mg/0.8 mL; 
- etanercept 40 mg/0.4 mL. 
- golimumab 
- infliximab 

 *including quality-assured biosimilars 

Oral liquid: 10 mg/mL [c]. 

Powder for injection: 50 mg [c]; 100 mg (as sodium salt) in vial. 
azathioprine 

Tablet: 25 mg [c]. 

Tablet (scored): 50 mg. 

Capsule: 25 mg. 

ciclosporin Concentrate for injection: 50 mg/mL in 1 mL ampoule.  

Oral liquid: 100 mg/mL [c]. 

Capsule (immediate-release): 0.5 mg; 0.75 mg; 1 mg; 2 mg; 
5 mg. 

tacrolimus 
Granules for oral supsension: 0.2 mg; 1 mg. 

Injection: 5 mg/mL in 1 mL vial.  

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 26 



WHO Model List of Essential Medicines – 23rd List (2023)  

8.2 Antineoplastics and supportive medicines  

Medicines listed below should be used according to protocols for treatment of the diseases. 

8.2.1 Cytotoxic medicines 

Complementary List 

Concentrate for solution for infusion: 1 mg/mL; 2 mg/mL. 
arsenic trioxide 

− Acute promyelocytic leukaemia 

asparaginase* Powder for injection: 10 000 IU in vial. 

*including quality-assured biosimilars − Acute lymphoblastic leukaemia. 

Injection: 45 mg/0.5 mL; 180 mg/2 mL. 

bendamustine − Chronic lymphocytic leukaemia  
− Follicular lymphoma  

Powder for injection: 15 000 IU (as sulfate) in vial. 

− Hodgkin lymphoma 
bleomycin − Kaposi sarcoma 

− Ovarian germ cell tumour 
− Testicular germ cell tumour 

Injection: 3 mg/mL in 10 mL ampoule; 7.5 mg/mL in 2 mL 
ampoule; 10 mg/mL in 5 mL ampoule. 

Tablet: 5 mg; 15 mg; 25 mg. 

calcium folinate (leucovorin calcium) − Burkitt lymphoma  

 − Early stage colon cancer 
− Early stage rectal cancer 
− Gestational trophoblastic neoplasia 
− Metastatic colorectal cancer 
− Osteosarcoma 

Tablet: 150 mg; 500 mg. 

− Early stage colon cancer 
capecitabine − Early stage rectal cancer 

− Metastatic breast cancer 
− Metastatic colorectal cancer 

Injection: 50 mg/5 mL; 150 mg/15 mL; 450 mg/45 mL; 
600 mg/60 mL. 

− Cervical cancer  
− Early stage breast cancer 
− Epithelial ovarian cancer 
− Head and neck cancer (as a radio-sensitizer) 

carboplatin − Low-grade glioma 
− Nasopharyngeal cancer 
− Nephroblastoma (Wilms tumour) 
− Non-small cell lung cancer 
− Osteosarcoma 
− Ovarian germ cell tumour 
− Retinoblastoma 
− Testicular germ cell tumour 

Tablet: 2 mg. 
chlorambucil 

− Chronic lymphocytic leukaemia 

 WHO Model List of Essential Medicines – 23rd List (2023) page 27 



WHO Model List of Essential Medicines – 23rd List (2023)  

Injection: 10 mg/10 mL; 20 mg/20 mL; 50 mg/50 mL; 
100 mg/100 mL. 

− Cervical cancer  
− Head and neck cancer (as a radio-sensitizer) 

cisplatin − Low-grade glioma 
− Nasopharyngeal cancer (as a radio-sensitizer) 
− Non-small cell lung cancer 
− Osteosarcoma 
− Ovarian germ cell tumour 
− Testicular germ cell tumour 

Powder for injection: 500 mg; 1 g; 2 g in vial. 

Solid oral dosage form: 25 mg; 50 mg. 

− Acute lymphoblastic leukaemia 
− Anaplastic large cell lymphoma  
− Burkitt lymphoma 
− Chronic lymphocytic leukaemia 
− Diffuse large B-cell lymphoma 
− Early stage breast cancer 

cyclophosphamide 
− Ewing sarcoma 
− Follicular lymphoma  
− Gestational trophoblastic neoplasia 
− Hodgkin lymphoma 
− Low-grade glioma 
− Metastatic breast cancer 
− Multiple myeloma 
− Nephroblastoma (Wilms tumour) 
− Rhabdomyosarcoma 

Injection: 100 mg/mL in vial 

Powder for injection: 100 mg in vial. 

− Acute lymphoblastic leukaemia 
cytarabine − Acute myeloid leukaemia 

− Acute promyelocytic leukaemia 
− Anaplastic large cell lymphoma  
− Burkitt lymphoma 
− Langerhans cell histiocytosis 

Powder for injection: 100 mg; 200 mg in vial. 
dacarbazine 

− Hodgkin lymphoma 

Powder for injection: 500 micrograms in vial. 

dactinomycin − Ewing sarcoma  
− Gestational trophoblastic neoplasia 

 
− Nephroblastoma (Wilms tumour) 
− Rhabdomyosarcoma 

Injection: 2 mg/mL; 5 mg/mL (as hydrochloride) in vial.  

Powder for injection: 20 mg; 50 mg (as hydrochloride) in vial. 
daunorubicin 

− Acute lymphoblastic leukaemia 
− Acute myeloid leukaemia 
− Acute promyelocytic leukaemia 

 WHO Model List of Essential Medicines – 23rd List (2023) page 28 



WHO Model List of Essential Medicines – 23rd List (2023)  

Injection: 20 mg/mL; 40 mg/mL. 

docetaxel − Early stage breast cancer 
− Metastatic breast cancer 
− Metastatic prostate cancer 

Injection: 2 mg/mL (hydrochloride) in vial. 

Powder for injection: 10 mg; 50 mg (hydrochloride) in vial. 

− Acute lymphoblastic leukaemia 
− Anaplastic large cell lymphoma  
− Burkitt lymphoma 
− Diffuse large B-cell lymphoma 
− Early stage breast cancer 

doxorubicin 
− Ewing sarcoma 
− Follicular lymphoma 
− Hodgkin lymphoma 
− Kaposi sarcoma 
− Metastatic breast cancer 
− Multiple myeloma  
− Nephroblastoma (Wilms tumour) 
− Osteosarcoma 

Injection: 2 mg/mL (hydrochloride) in 10 mL, 25 mL vial 
doxorubicin (as pegylated liposomal) 

− Kaposi sarcoma 

Capsule: 50 mg, 100 mg. 

Injection: 20 mg/mL in 5 mL ampoule. 

Powder for injection: 100 mg (as phosphate) in vial 

− Acute lymphoblastic leukaemia 
− Acute myeloid leukaemia  
− Anaplastic large cell lymphoma  
− Burkitt lymphoma 

etoposide − Ewing sarcoma 
− Gestational trophoblastic neoplasia 
− Hodgkin lymphoma 
− Nephroblastoma (Wilms tumour) 
− Non-small cell lung cancer 
− Osteosarcoma 
− Ovarian germ cell tumour 
− Retinoblastoma 
− Testicular germ cell tumour 

Powder for injection: 50 mg (phosphate) in vial. 

fludarabine Tablet: 10 mg 

− Chronic lymphocytic leukaemia. 

Injection: 50 mg/mL in vial. 

− Early stage breast cancer 

fluorouracil − Early stage colon cancer 
− Early stage rectal cancer 
− Metastatic colorectal cancer 
− Nasopharyngeal cancer 

Powder for injection: 200 mg; 1 g in vial. 

gemcitabine − Epithelial ovarian cancer 
− Non-small cell lung cancer 

 WHO Model List of Essential Medicines – 23rd List (2023) page 29 



WHO Model List of Essential Medicines – 23rd List (2023)  

Solid oral dosage form: 100 mg [c]; 200 mg; 300 mg; 400 mg; 

hydroxycarbamide (hydroxyurea) 500 mg; 1 g. 

− Chronic myeloid leukaemia 

Powder for injection: 500 mg; 1 g; 2 g in vial. 

− Anaplastic large cell lymphoma  
− Burkitt lymphoma 
− Ewing sarcoma 

ifosfamide − Nephroblastoma (Wilms tumour) 
− Ovarian germ cell tumour 
− Osteosarcoma 
− Rhabdomyosarcoma 
− Testicular germ cell tumour  

Injection: 40 mg/2 mL in 2 mL vial; 100 mg/5 mL in 5 mL vial; 
500 mg/25 mL in 25 mL vial. 

irinotecan − Metastatic colorectal cancer 
− Nephroblastoma (Wilms tumour) 
− Rhabdomyosarcoma 

Tablet: 2 mg 

melphalan Powder for injection: 50 mg in vial 

− Multiple myeloma 

Tablet: 50 mg. 

Oral liquid: 20 mg/mL [c]. 
mercaptopurine 

− Acute lymphoblastic leukaemia 
− Acute promyelocytic leukaemia. 
− Langerhans cell histiocytosis 

Concentrated injection: 1000 mg/10 mL. 

Injection: 50mg/2 mL. 

Powder for injection: 50 mg (as sodium) in vial. 

Tablet: 2.5 mg (as sodium). 

methotrexate − Acute lymphoblastic leukaemia 
− Acute promyelocytic leukaemia 
− Anaplastic large cell lymphoma  
− Burkitt lymphoma 
− Early stage breast cancer 
− Gestational trophoblastic neoplasia 
− Langerhans cell histiocytosis 
− Osteosarcoma 

Injection: 50 mg/10 mL in 10 mL vial; 100 mg/20 mL in 20 mL 
vial; 200 mg/40 mL in 40 mL vial. 

oxaliplatin Powder for injection: 50 mg; 100 mg in vial.  

− Early stage colon cancer 
− Metastatic colorectal cancer 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 30 



WHO Model List of Essential Medicines – 23rd List (2023)  

Injection: 6 mg/mL in vial. 

− Cervical cancer  
− Epithelial ovarian cancer 
− Early stage breast cancer 

paclitaxel − Metastatic breast cancer 
− Kaposi sarcoma 
− Nasopharyngeal cancer 
− Non-small cell lung cancer 
− Ovarian germ cell tumour 

Injection: 3750 units/5 mL in vial. 
pegaspargase* 

Powder for injection: 3750 units in vial. 
*including quality-assured biosimilars 

− Acute lymphoblastic leukaemia 

Capsule: 50 mg (as hydrochloride). 
procarbazine [c] 

− Hodgkin lymphoma  

Tablet: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg). 
realgar-Indigo naturalis formulation 

− Acute promyelocytic leukaemia 

Solid oral dosage form: 40 mg. 
tioguanine [c] 

− Acute lymphoblastic leukaemia 

Injection: 10 mg/10 mL (sulfate) in vial. 

Powder for injection: 10 mg (sulfate) in vial. 

− Anaplastic large cell lymphoma  
− Hodgkin lymphoma 

vinblastine 
− Kaposi sarcoma 
− Langerhans cell histiocytosis 
− Low-grade glioma  
− Ovarian germ cell tumour 
− Testicular germ cell tumour 

Injection: 1 mg/mL (sulfate); 2 mg/2 mL (sulfate) in vial. 

Powder for injection: 1 mg; 5 mg (sulfate) in vial. 

− Acute lymphoblastic leukaemia 
− Burkitt lymphoma 
− Diffuse large B-cell lymphoma 
− Ewing sarcoma 
− Follicular lymphoma 

vincristine 
− Gestational trophoblastic neoplasia 
− Hodgkin lymphoma 
− Kaposi sarcoma 
− Langerhans cell histiocytosis 
− Low-grade glioma  
− Nephroblastoma (Wilms tumour) 
− Retinoblastoma 
− Rhabdomyosarcoma 

Capsule: 20 mg; 30 mg; 80 mg. 

Injection: 10 mg/mL in 1 mL, 5 mL vial. 
vinorelbine 

− Non-small cell lung cancer 
− Metastatic breast cancer 
− Rhabdomyosarcoma  

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 31 



WHO Model List of Essential Medicines – 23rd List (2023)  

8.2.2 Targeted therapies  

Complementary List 

Capsule: 10 mg. 
all-trans retinoid acid (ATRA) 

− Acute promyelocytic leukaemia. 

Powder for injection: 3.5 mg in vial. 
bortezomib 

− Multiple myeloma  

Tablet: 20 mg; 50 mg; 70 mg; 80 mg; 100 mg; 140 mg. 
dasatinib 

− Imatinib-resistant chronic myeloid leukaemia  

 erlotinib 
Tablet: 100 mg, 150 mg. 

Therapeutic alternatives:  
− EGFR mutation-positive advanced non-small cell lung 

- afatinib cancer 
- gefitinib 

Tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg. 

everolimus  Tablet (dispersible): 2 mg; 3 mg; 5 mg. 

− Subependymal giant cell astrocytoma 

Capsule: 140 mg. 
ibrutinib 

− Relapsed/refractory chronic lymphocytic leukaemia 

Solid oral dosage form: 100 mg; 400 mg. 

− Chronic myeloid leukaemia 
imatinib − Gastrointestinal stromal tumour 

− Philadelphia chromosome positive acute lymphoblastic 
leukaemia  

Capsule: 150 mg; 200 mg. 
nilotinib 

− Imatinib-resistant chronic myeloid leukaemia  

Injection (intravenous): 100 mg/10 mL in 10 mL vial; 
500 mg/50 mL in 50 mL vial. 

rituximab* 
− Burkitt lymphoma 

*including quality-assured biosimilars − Diffuse large B-cell lymphoma 
− Chronic lymphocytic leukaemia 
− Follicular lymphoma 

Powder for injection: 60 mg; 150 mg; 440 mg in vial. 
trastuzumab* 

− Early stage HER2-positive breast cancer 
*including quality-assured biosimilars 

− Metastatic HER2-positive breast cancer  

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 32 



WHO Model List of Essential Medicines – 23rd List (2023)  

8.2.3 Immunomodulators 

Complementary List 

Injection: 120 micrograms/0.2 mL; 300 micrograms/0.5 mL; 
480 micrograms/0.8 mL in pre-filled syringe. 

Injection: 300 micrograms/mL in 1 mL vial; 480 micrograms/1.6 
mL in 1.6 mL vial. 

filgrastim* − Primary prophylaxis in patients at high risk for developing 

*including quality-assured biosimilars febrile neutropenia associated with myelotoxic 
chemotherapy. 

− Secondary prophylaxis for patients who have experienced 
neutropenia following prior myelotoxic chemotherapy 

− To facilitate administration of dose dense chemotherapy 
regimens 

Capsule: 25 mg. 
lenalidomide 

− Multiple myeloma 

 nivolumab* Concentrate solution for infusion: 10 mg/mL. 

Therapeutic alternatives*:  − Metastatic melanoma 

- pembrolizumab 
 
*including quality-assured biosimilars 

Injection: 6 mg/0.6 mL in pre-filled syringe. 

− Primary prophylaxis in patients at high risk for developing 
febrile neutropenia associated with myelotoxic 

pegfilgrastim* 
chemotherapy 

*including quality-assured biosimilars − Secondary prophylaxis for patients who have experienced 
neutropenia following prior myelotoxic chemotherapy 

− To facilitate administration of dose dense chemotherapy 
regimens 

Capsule: 50 mg. 
thalidomide 

− Multiple myeloma 

8.2.4 Hormones and antihormones 

Complementary List 

 abiraterone Tablet: 250 mg; 500 mg. 

Therapeutic alternatives:  − Metastatic castration-resistant prostate cancer 

- enzalutamide 

 anastrozole Tablet: 1 mg. 

Therapeutic alternatives: − Early stage breast cancer 
− Metastatic breast cancer 

- 4th level ATC chemical subgroup (L02BG 
Aromatase inhibitors) 

 bicalutamide Tablet: 50 mg. 

Therapeutic alternatives: − Metastatic prostate cancer 

- flutamide 
- nilutamide 

 WHO Model List of Essential Medicines – 23rd List (2023) page 33 



WHO Model List of Essential Medicines – 23rd List (2023)  

Injection: 4 mg/mL (as disodium phosphate salt) in 1 mL ampoule. 

Oral liquid: 2 mg/5 mL [c]. 

Tablet: 2 mg [c]; 4 mg. 
dexamethasone 

− Acute lymphoblastic leukaemia 
− Anaplastic large cell lymphoma  
− Burkitt lymphoma  
− Multiple myeloma 

Powder for injection: 100 mg (as sodium succinate) in vial. 

hydrocortisone − Acute lymphoblastic leukaemia 
− Burkitt lymphoma 

Injection: 7.5 mg; 22.5 mg in pre-filled syringe. 
 leuprorelin  

Therapeutic alternatives: − Early stage breast cancer 
− Metastatic prostate cancer. 

- goserelin 
- triptorelin 

Injection: 40 mg/mL (as sodium succinate) in 1 mL single-dose 
vial and 5 mL multi-dose vials; 80 mg/mL (as sodium succinate) in 

methylprednisolone [c] 1 mL single-dose vial. 

− Acute lymphoblastic leukamia 
− Burkitt lymphoma 

Oral liquid: 5 mg/mL [c]. 

Tablet: 5 mg; 25 mg. 

− Acute lymphoblastic leukaemia 
− Anaplastic large cell lymphoma  

 prednisolone 
− Burkitt lymphoma 

Therapeutic alternatives: − Chronic lymphocytic leukaemia 
− Diffuse large B-cell lymphoma 

- prednisone 
− Follicular lymphoma 
− Hodgkin lymphoma 
− Langerhans cell histiocytosis 
− Metastatic castration-resitsant prostate cancer 
− Multiple myeloma 

Tablet: 10 mg; 20 mg (as citrate). 

tamoxifen − Early stage breast cancer 
− Metastatic breast cancer. 

8.2.5 Supportive medicines 

Complementary List 

Tablet: 100 mg; 300 mg. 
allopurinol [c]  

− Tumour lysis syndrome 

Injection: 100 mg/mL in 4 mL and 10 mL ampoules. 

Tablet: 400 mg; 600 mg. 

− Burkitt lymphoma 

mesna − Ewing sarcoma 
− Nephroblastoma (Wilms tumour) 
− Ovarian germ cell tumour 
− Osteosarcoma 
− Rhabdomyosarcoma 
− Testicular germ cell tumour 

 WHO Model List of Essential Medicines – 23rd List (2023) page 34 



WHO Model List of Essential Medicines – 23rd List (2023)  

Powder and solvent for solution for infusion: 1.5 mg; 7.5 mg in 

rasburicase vial. 

− Tumour lysis syndrome 

Concentrate solution for infusion: 4 mg/5 mL in 5 mL vial. 

zoledronic acid Solution for infusion: 4 mg/100 mL in 100 mL bottle. 

− Malignancy-related bone disease 

9. THERAPEUTIC FOODS 

Biscuit or paste*. 

ready-to-use therapeutic food [c] *of nutritional composition as determined by the UN joint 
statement on the community-based management of severe acute 
malnutrition and Codex alimentarius guidelines. 

10. MEDICINES AFFECTING THE BLOOD 

10.1 Antianaemia medicines 

Oral liquid: equivalent to 25 mg iron (as sulfate)/mL. 
ferrous salt 

Tablet: equivalent to 60 mg iron. 

Tablet: equivalent to 60 mg elemental iron + 400 micrograms folic 
acid.* 

ferrous salt + folic acid  *nutritional supplement for use during pregnancy 

Tablet: equivalent to 60 mg elemental iron + 2.8 mg folic acid.** 

**for weekly iron and folic acid supplementation 

Tablet: 400 micrograms*; 1 mg; 5 mg. 

folic acid *periconceptual use for prevention of first occurrence of neural 
tube defects 

Injection: 1 mg/mL (as acetate, as hydrochloride or as sulfate) in 
hydroxocobalamin 

1 mL ampoule. 

Complementary List 

 erythropoiesis-stimulating agents* 

Therapeutic alternatives:  Injection:  pre-filled syringe 

- epoetin alfa, beta and theta 1000 IU/0.5 mL; 2000 IU/0.5 mL; 3000 IU/0.3 mL; 
- darbepoetin alfa 4000 IU/0.4 mL; 5000 IU/0.5 mL; 6000 IU/0.6 mL; 
- methoxy polyethylene glycol-epoetin beta 8000 IU/0.8mL; 10 000 IU/1 mL; 20 000 IU/0.5 mL; 
 40 000 IU/1 mL.  
*including quality-assured biosimilars 
 

10.2 Medicines affecting coagulation 

 dabigatran 

Therapeutic alternatives: 
Capsule: 110 mg; 150 mg. 

- apixaban 
- edoxaban 
- rivaroxaban 
 

 WHO Model List of Essential Medicines – 23rd List (2023) page 35 



WHO Model List of Essential Medicines – 23rd List (2023)  

o enoxaparin* 

Therapeutic alternatives*: Injection: ampoule or pre-filled syringe 

- dalteparin 20 mg/0.2 mL; 40 mg/0.4 mL; 60 mg/0.6 mL; 80 mg/0.8 mL; 
- nadroparin 100 mg/1 mL; 120 mg/0.8 mL; 150 mg/1 mL. 
 
*including quality-assured biosimilars 

Injection: 1000 IU/mL; 5000 IU/mL; 20 000 IU/mL in 1 mL 
heparin sodium 

ampoule. 

Injection: 1 mg/mL [c]; 10 mg/mL in ampoule. 
phytomenadione 

Tablet: 10 mg. 

protamine sulfate Injection: 10 mg/mL in 5 mL ampoule. 

tranexamic acid Injection: 100 mg/mL in 10 mL ampoule. 

 warfarin 
Tablet: 1 mg; 2 mg; 5 mg (sodium). 

Therapeutic alternatives to be reviewed 
 

Complementary List  

Injection: 4 micrograms/mL (as acetate) in 1 mL ampoule. 
desmopressin[c] 

Nasal spray: 10 micrograms (as acetate) per dose. 

heparin sodium [c] Injection: 1000 IU/mL; 5000 IU/mL in 1 mL ampoule. 

protamine sulfate [c] Injection: 10 mg/mL in 5 mL ampoule. 

 warfarin [c] 
Tablet: 0.5 mg; 1 mg; 2 mg; 5 mg (sodium). 

Therapeutic alternatives to be reviewed 

10.3 Other medicines for haemoglobinopathies 

 deferasirox 
Tablet (dispersible): 100 mg; 125 mg; 250 mg; 400 mg; 500 mg. 

Therapeutic alternatives: 
Tablet (film-coated): 90 mg; 180 mg; 360 mg. 

- deferiprone 

Complementary List 

deferoxamine Powder for injection: 500 mg (mesilate) in vial. 

hydroxycarbamide (hydroxyurea) Solid oral dosage form: 100 mg [c]; 200 mg; 500 mg; 1 g. 

11. BLOOD PRODUCTS OF HUMAN ORIGIN AND PLASMA SUBSTITUTES 

11.1 Blood and blood components 

In accordance with the World Health Assembly resolution WHA63.12, WHO recognizes that achieving self-sufficiency, unless special 
circumstances preclude it, in the supply of safe blood components based on voluntary, non-remunerated blood donation, and the 
security of that supply are important national goals to prevent blood shortages and meet the transfusion requirements of the patient 
population. All preparations should comply with the WHO requirements. 

 cryoprecipitate, pathogen-reduced Injection: frozen liquid in bag or lyophilized powder in vial 
containing: 

Therapeutic alternatives: 
- > 50 IU Factor VIII 

- cryoprecipitate (not pathogen-reduced) - > 100 IU vWF 
- > 140 mg clottable fibrinogen per unit 

fresh-frozen plasma   

platelets   

red blood cells   

 WHO Model List of Essential Medicines – 23rd List (2023) page 36 



WHO Model List of Essential Medicines – 23rd List (2023)  

whole blood   

11.2 Plasma-derived medicines 

All human plasma-derived medicines should comply with the WHO requirements.  

11.2.1 Human immunoglobulins 

anti-D immunoglobulin  Injection: 250 micrograms in single-dose vial. 

anti-rabies immunoglobulin  Injection: 150 IU/mL in vial. 

anti-tetanus immunoglobulin Injection: 500 IU in vial. 

Complementary List  

Intramuscular administration: 16% protein solution. 

Subcutaneous administration: 15%; 16% protein solution. 

− Primary immune deficiency. 
 

normal immunoglobulin 
Intravenous administration: 5%; 10% protein solution. 

− Primary immune deficiency 
− Kawasaki disease 
− Langerhans cell histiocytosis 

11.2.2 Blood coagulation factors 

Complementary List 

coagulation factor VIII  Powder for injection: 250 IU; 500 IU; 1000 IU in vial. 

 coagulation factor IX  

Therapeutic alternatives: Powder for injection: 500 IU; 1000 IU in vial. 

- coagulation factor IX complex 

11.3 Plasma substitutes 

 dextran 70 

Therapeutic alternatives: Injectable solution: 6%. 
 
- polygeline injectable solution 3.5% 

12. CARDIOVASCULAR MEDICINES 

12.1 Antianginal medicines 

 bisoprolol 

Therapeutic alternatives: 
Tablet: 1.25 mg; 5 mg. 

- carvedilol 
- metoprolol 
 

glyceryl trinitrate Tablet (sublingual): 500 micrograms. 

isosorbide dinitrate Tablet (sublingual): 5 mg. 

verapamil Tablet: 40 mg; 80 mg (hydrochloride). 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 37 



WHO Model List of Essential Medicines – 23rd List (2023)  

12.2 Antiarrhythmic medicines 

 bisoprolol 

Therapeutic alternatives: 
Tablet: 1.25 mg; 5 mg. 

- carvedilol 
- metoprolol 
 

Injection: 250 micrograms/mL in 2 mL ampoule. 

digoxin Oral liquid: 50 micrograms/mL.  

Tablet: 62.5 micrograms; 250 micrograms. 

Injection: 100 micrograms/mL (as acid tartrate or hydrochloride) 
epinephrine (adrenaline) 

in 10 mL ampoule. 

lidocaine Injection: 20 mg/mL (hydrochloride) in 5 mL ampoule. 

Injection: 2.5 mg/mL (hydrochloride) in 2 mL ampoule. 
verapamil 

Tablet: 40 mg; 80 mg (hydrochloride). 

Complementary List  

Injection: 50 mg/mL (hydrochloride) in 3 mL ampoule. 
amiodarone 

Tablet: 100 mg; 200 mg; 400 mg (hydrochloride). 

12.3 Antihypertensive medicines 

 amlodipine 

Therapeutic alternatives: Tablet: 5 mg (as maleate, mesylate or besylate). 
 
- 4th level ATC chemical subgroup (C08CA 
Dihydropyridine derivatives) 

 bisoprolol 
Tablet: 1.25 mg; 5 mg. 

Therapeutic alternatives: 
*atenolol should not be used as a first-line agent in uncomplicated 

- atenolol* hypertension in patients > 60 years 
- carvedilol 
- metoprolol 

 enalapril 
Oral liquid: 1 mg/mL (as hydrogen maleate) [c]. 

Therapeutic alternatives: 

- 4th level ATC chemical subgroup (C09AA ACE Tablet: 2.5 mg; 5 mg; 10 mg (as hydrogen maleate). 

inhibitors, plain) 

Powder for injection: 20 mg (hydrochloride) in ampoule. 

Tablet: 25 mg; 50 mg (hydrochloride). 

hydralazine* *Hydralazine is listed for use only in the acute management of severe 
pregnancy-induced hypertension. Its use in the treatment of essential 
hypertension is not recommended in view of the evidence of greater 
efficacy and safety of other medicines. 

 hydrochlorothiazide 

Therapeutic alternatives: Oral liquid: 50 mg/5 mL. 

- chlorothiazide 
Solid oral dosage form: 12.5 mg; 25 mg. 

- chlorthalidone 
- indapamide 
 

 WHO Model List of Essential Medicines – 23rd List (2023) page 38 



WHO Model List of Essential Medicines – 23rd List (2023)  

o lisinopril +  amlodipine 

Therapeutic alternatives: 

- 4th level ATC chemical subgroup (C09AA ACE Tablet: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg. 
inhibitors, plain) (for lisinopril) 

- 4th level ATC chemical subgroup (C08CA 
Dihydropyridine derivatives) (for amlodipine) 

 lisinopril +  hydrochlorothiazide 

Therapeutic alternatives: 

- 4th level ATC chemical subgroup (C09AA ACE Tablet: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg. 
inhibitors, plain) (for lisinopril) 

- chlorthalidone, chlorothiazide, indapamide (for 
hydrochlorothiazide) 

 losartan 

Therapeutic alternatives: 
Tablet: 25 mg; 50 mg; 100 mg. 

- 4th level ATC chemical subgroup (C09CA Angiotensin II 
receptor blockers (ARBs), plain) 

Tablet: 250 mg. 

*Methyldopa is listed for use only in the management of pregnancy-
methyldopa* induced hypertension. Its use in the treatment of essential hypertension 

is not recommended in view of the evidence of greater efficacy and 
safety of other medicines. 

 telmisartan +  amlodipine 

Therapeutic alternatives: 

- 4th level ATC chemical subgroup (C09CA Angiotensin II Tablet: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg. 
receptor blockers (ARBs), plain) (for telmisartan) 

- 4th level ATC chemical subgroup (C08CA 
Dihydropyridine derivatives) (for amlodipine) 

 telmisartan +  hydrochlorothiazide 

Therapeutic alternatives: 

- 4th level ATC chemical subgroup (C09CA Angiotensin II Tablet: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg. 
receptor blockers (ARBs), plain) (for telmisartan) 

- chlorthalidone, chlorothiazide, indapamide (for 
hydrochlorothiazide) 

Complementary List 

sodium nitroprusside Powder for infusion: 50 mg in ampoule. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 39 



WHO Model List of Essential Medicines – 23rd List (2023)  

12.4 Medicines used in heart failure 

 bisoprolol 

Therapeutic alternatives: Tablet: 1.25 mg; 5 mg. 

- carvedilol 
- metoprolol 

Injection: 250 micrograms/mL in 2 mL ampoule. 

digoxin Oral liquid: 50 micrograms/mL. 

Tablet: 62.5 micrograms; 250 micrograms. 

 enalapril 

Therapeutic alternatives: 
Tablet: 2.5 mg; 5 mg; 10 mg (as hydrogen maleate). 

- 4th level ATC chemical subgroup (C09AA ACE 
inhibitors, plain) 

 furosemide 
Injection: 10 mg/mL in 2 mL, 5 mL ampoule. 

Therapeutic alternatives: 
Oral liquid: 20 mg/5 mL; 50 mg/5 mL [c]. 

- bumetanide 
- torasemide Tablet: 20 mg; 40 mg. 

 

 hydrochlorothiazide 

Therapeutic alternatives: Oral liquid: 50 mg/5 mL. 

- chlorothiazide Solid oral dosage form: 25 mg. 
- chlorthalidone 
- indapamide 

 losartan 

Therapeutic alternatives: 
Tablet: 25 mg; 50 mg; 100 mg. 

- 4th level ATC chemical subgroup (C09CA Angiotensin II 
receptor blockers (ARBs), plain) 

spironolactone Tablet: 25 mg. 

Complementary List 

Injection: 100 micrograms/mL in 1 mL ampoule; 
250 micrograms/mL in 2 mL ampoule.  

digoxin [c] 
Oral liquid: 50 micrograms/mL.  

Tablet: 62.5 micrograms; 125 micrograms; 250 mg micrograms. 

dopamine Injection: 40 mg/mL (hydrochloride) in 5 mL vial. 

12.5 Antithrombotic medicines 

12.5.1 Anti-platelet medicines 

acetylsalicylic acid  Tablet: 100 mg. 

clopidogrel  Tablet: 75 mg; 300 mg 

12.5.2 Thrombolytic medicines 

Complementary List 

alteplase Powder for injection: 10 mg; 20 mg; 50 mg in vial 

streptokinase Powder for injection: 1.5 million IU in vial. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 40 



WHO Model List of Essential Medicines – 23rd List (2023)  

12.6 Lipid-lowering agents 

 simvastatin* 

Therapeutic alternatives: 
Tablet: 5 mg; 10 mg; 20 mg; 40 mg. 

- atorvastatin 
- fluvastatin *For use in high-risk patients. 
- lovastatin 
- pravastatin 
 
12.7 Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease 

acetylsalicylic acid +  atorvastatin +  ramipril 

Therapeutic alternatives: Tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 
- fluvastatin, lovastatin, pravastatin, simvastatin (for 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 
atorvastatin) 40 mg + 5 mg; 100 mg + 40 mg + 10 mg. 
- 4th level ATC chemical subgroup (C09AA ACE 
inhibitors, plain) (for ramipril) 

acetylsalicylic acid +  simvastatin +  ramipril + 
 atenolol +  hydrochlorothiazide  

Therapeutic alternatives: 

- atorvastatin, fluvastatin, lovastatin, pravastatin (for 
simvastatin) Tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg. 
- 4th level ATC chemical subgroup (C09AA ACE 
inhibitors, plain) (for ramipril) 
- bisoprolol, carvedilol, metoprolol (for atenolol) 
- chlorthalidone, chlorothiazide, indapamide (for 
hydrochlorothiazide) 

 atorvastatin +  perindopril +  amlodipine 

Therapeutic alternatives: 

- fluvastatin, lovastatin, pravastatin, simvastatin (for Tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 
atorvastatin) 5 mg + 5 mg; 40 mg + 10 mg + 10 mg. 
- 4th level ATC chemical subgroup (C09AA ACE 
inhibitors, plain) (for perindopril) 
- 4th level ATC chemical subgroup (C08CA 
Dihydropyridine derivatives) (for amlodipine) 

13. DERMATOLOGICAL MEDICINES  

13.1 Antifungal medicines  

 miconazole 

Therapeutic alternatives: 
Cream or ointment: 2% (nitrate). 

- 4th level ATC chemical subgroup (D01AC Imidazole 
and triazole derivatives) excluding combinations 
 
selenium sulfide Detergent-based suspension: 2%. 

sodium thiosulfate Solution: 15%. 

terbinafine Cream or ointment: 1% (hydrochloride). 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 41 



WHO Model List of Essential Medicines – 23rd List (2023)  

13.2 Anti-infective medicines  

Cream: 2% (as calcium). 
mupirocin 

Ointment: 2%. 

potassium permanganate Aqueous solution: 1:10 000. 

Cream: 1%. 
silver sulfadiazine a  

a > 2 months. 

13.3 Anti-inflammatory and antipruritic medicines  

 betamethasone a  
Cream or ointment: 0.1% (as valerate). 

Therapeutic alternatives: 

- 4th level ATC chemical subgroup (D07AC a Hydrocortisone preferred in neonates. 

Corticosteroids, potent (group III)) 

calamine  Lotion. 

 hydrocortisone 

Therapeutic alternatives: 
Cream or ointment: 1% (acetate). 

- 4th level ATC chemical subgroup (D07AA 
Corticosteroids, weak (group I)) 

13.4 Medicines affecting skin differentiation and proliferation  

benzoyl peroxide Cream or lotion: 5%. 

 calcipotriol 
Cream or ointment: 50 micrograms/mL (0.005%). 

Therapeutic alternatives:  
Lotion: 50 micrograms/mL (0.005%). 

- calcitriol 
- tacalcitol 

coal tar Solution: 5%. 

fluorouracil Ointment: 5%. 

 podophyllum resin 

Therapeutic alternatives: Solution: 10% to 25%. 

- podophyllotoxin 

salicylic acid Solution: 5%. 

urea Cream or ointment: 5%; 10%. 

Complementary List 

methotrexate Tablet: 2.5 mg; 10 mg (as sodium). 

13.5 Scabicides and pediculicides  

 benzyl benzoate a  
Lotion: 25%. 

Therapeutic alternatives: 
a > 2 years. 

- precipitated sulfur topical ointment 

Cream: 5%. 
permethrin 

Lotion: 1%. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 42 



WHO Model List of Essential Medicines – 23rd List (2023)  

14. DIAGNOSTIC AGENTS 

14.1 Ophthalmic medicines 

fluorescein Eye drops: 1% (sodium salt). 

 tropicamide 

Therapeutic alternatives: 
Eye drops: 0.5%. 

- atropine 
- cyclopentolate 

14.2 Radiocontrast media 

 amidotrizoate Injection: 140 mg to 420 mg iodine/mL (as sodium or meglumine 
salt) in 20 mL ampoule. 

Therapeutic alternatives to be reviewed  

barium sulfate Aqueous suspension. 

 iohexol Injection: 140 mg to 350 mg iodine/mL in 5 mL, 10 mL, 20 mL 
ampoules. 

Therapeutic alternatives to be reviewed  

Complementary List  

barium sulfate [c] Aqueous suspension. 

 meglumine iotroxate 
Solution: 5 g to 8 g iodine in 100 mL to 250 mL. 

Therapeutic alternatives to be reviewed  

15. ANTISEPTICS AND DISINFECTANTS 

15.1 Antiseptics 

 chlorhexidine 
Solution: 5% (digluconate). 

Therapeutic alternatives to be reviewed  

 ethanol 

Therapeutic alternatives: Solution: 70% (denatured). 

- propanol 

 povidone iodine 

Therapeutic alternatives: Solution: 10% (equivalent to 1% available iodine). 

- iodine 

15.2 Disinfectants 

Solution: containing ethanol 80% volume/volume.  
alcohol based hand rub 

Solution: containing isopropyl alcohol 75% volume/volume. 

Liquid: (0.1% available chlorine) for solution.  

chlorine base compound Powder: (0.1% available chlorine) for solution. 

Solid: (0.1% available chlorine) for solution. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 43 



WHO Model List of Essential Medicines – 23rd List (2023)  

o chloroxylenol 

Therapeutic alternatives: 
Solution: 4.8%. 

- 4th level ATC chemical subgroup (D08AE Phenol and 
derivatives) 

glutaral Solution: 2%. 

16. DIURETICS 

amiloride Tablet: 5 mg (hydrochloride). 

 furosemide Injection: 10 mg/mL in 2 mL, 5 mL ampoule. 

Therapeutic alternatives: Oral liquid: 20 mg/5 mL; 50 mg/5 mL [c]. 

- bumetanide Tablet: 20 mg; 40 mg. 
- torasemide 
 hydrochlorothiazide 

Therapeutic alternatives: 
Solid oral dosage form: 25 mg. 

- chlorothiazide 
- chlortalidone 
- indapamide 
 
mannitol Injectable solution: 10%; 20%. 

spironolactone Tablet: 25 mg. 

Complementary List  

 hydrochlorothiazide[c] 

Therapeutic alternatives: Tablet (scored): 25 mg. 

- chlorothiazide 
- chlortalidone 

mannitol [c] Injectable solution: 10%; 20%. 

Oral liquid: 5 mg/5 mL; 10 mg/5 mL; 25 mg/5 mL. 
spironolactone[c] 

Tablet: 25 mg. 

17. GASTROINTESTINAL MEDICINES 

Complementary List  

Age-appropriate formulations and doses including lipase, 
pancreatic enzymes[c] 

protease and amylase. 

17.1 Antiulcer medicines 

 omeprazole 
Powder for injection: 40 mg in vial 

Therapeutic alternatives: 
Powder for oral liquid: 20 mg; 40 mg sachets. 

- 4th level ATC chemical subgroup (A02BC Proton pump 
Solid oral dosage form: 10 mg; 20 mg; 40 mg. 

inhibitors) excluding combinations  

 ranitidine 
Injection: 25 mg/mL (as hydrochloride) in 2 mL ampoule. 

Therapeutic alternatives: 
Oral liquid: 75 mg/5 mL (as hydrochloride). 

- 4th level ATC chemical subgroup (A02BA H2-receptor 
Tablet: 150 mg (as hydrochloride). 

antagonists) excluding combinations 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 44 



WHO Model List of Essential Medicines – 23rd List (2023)  

17.2 Antiemetic medicines 

Injection: 4 mg/mL (as disodium phosphate salt) in 1 mL ampoule. 

dexamethasone Oral liquid: 0.5 mg/5 mL; 2 mg/5 mL. 

Solid oral dosage form: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg. 

Injection: 5 mg/mL (hydrochloride) in 2 mL ampoule. 

Oral liquid: 5 mg/5 mL [c]. 
metoclopramide a  

Tablet: 10 mg (hydrochloride). 

a Not in neonates. 

 ondansetron a Injection: 2 mg base/mL in 2 mL ampoule (as hydrochloride). 

Therapeutic alternatives: Oral liquid: 4 mg base/5 mL. 

- dolasetron Solid oral dosage form: Eq 4 mg base; Eq 8 mg base; Eq 24 mg 
- granisetron base. 
- palonosetron 
- tropisetron a > 1 month. 

Complementary list 

Capsule: 80 mg; 125 mg; 165 mg 
aprepitant 

Powder for oral suspension: 125 mg in sachet 

17.3 Anti-inflammatory medicines 

Retention enema. 
 sulfasalazine 

Therapeutic alternatives: Suppository: 500 mg. 

- mesalazine Tablet: 500 mg. 

Complementary List 

Retention enema: 100 mg/60 mL. 
hydrocortisone 

Suppository: 25 mg (acetate). 

prednisolone Retention enema: 20 mg/100 mL (as sodium phosphate). 

17.4 Laxatives 

 senna 

Therapeutic alternatives: Tablet: 7.5 mg (sennosides) (or traditional dosage forms). 

- bisacodyl 

17.5 Medicines used in diarrhoea 

Co-package containing: 

oral rehydration salts – zinc sulfate [c] ORS powder for dilution (see Section 17.5.1) – zinc sulfate solid 
oral dosage form 20 mg (see Section 17.5.2) 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 45 



WHO Model List of Essential Medicines – 23rd List (2023)  

17.5.1 Oral rehydration 

Powder for dilution in 200 mL; 500 mL; 1 L. 
 
glucose:   75 mEq  
sodium:   75 mEq or mmol/L 
chloride:   65 mEq or mmol/L 
potassium:   20 mEq or mmol/L 
citrate:   10 mmol/L 
osmolarity:   245 mOsm/L  

oral rehydration salts glucose:   13.5 g/L  
sodium chloride:  2.6 g/L 
potassium chloride:  1.5 g/L  
trisodium citrate dihydrate*: 2.9 g/L 

*trisodium citrate dihydrate may be replaced by sodium hydrogen 
carbonate (sodium bicarbonate) 2.5 g/L. However, as the stability 
of this latter formulation is very poor under tropical conditions, it is 
recommended only when manufactured for immediate use.  

17.5.2 Medicines for diarrhoea 

Solid oral dosage form: 20 mg. 

zinc sulfate* *In acute diarrhoea zinc sulfate should be used as an adjunct to 
oral rehydration salts. 

18. MEDICINES FOR ENDOCRINE DISORDERS 

18.1 Adrenal hormones and synthetic substitutes 

fludrocortisone  Tablet: 100 micrograms (acetate). 

hydrocortisone  Tablet: 5 mg; 10 mg; 20 mg. 

18.2 Androgens 

Complementary List 

testosterone Injection: 200 mg (enanthate) in 1 mL ampoule. 

18.3 Estrogens  

18.4 Progestogens 

 medroxyprogesterone acetate 

Therapeutic alternatives: Tablet: 5 mg. 

- norethisterone 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 46 



WHO Model List of Essential Medicines – 23rd List (2023)  

18.5 Medicines for diabetes 

18.5.1 Insulins 

insulin injection (soluble)* Injection: 40 IU/mL in 10 mL vial; 100 IU/mL in 10 mL vial; 

*including quality-assured biosimilars 100 IU/mL in 3 mL cartridge or pre-filled pen.  

intermediate-acting insulin*  Injection: 40 IU/mL in 10 mL vial; 100 IU/mL in 10 mL vial; 
100 IU/mL in 3 mL cartridge or pre-filled pen (as compound 

*including quality-assured biosimilars insulin zinc suspension or isophane insulin). 

 long-acting insulin analogues* 

Therapeutic alternatives: 

- insulin degludec Injection: 100 IU/mL in 3 mL cartridge or pre-filled pen.  
- insulin detemir 
- insulin glargine 
 
*including quality-assured biosimilars 

18.5.2 Oral hypoglycaemic agents 

 empagliflozin 

Therapeutic alternatives: Tablet: 10 mg; 25 mg. 
- canagliflozin 
- dapagliflozin 

 gliclazide* Solid oral dosage form: (controlled-release tablets) 30 mg; 60 mg; 

Therapeutic alternatives: 80 mg. 

- 4th level ATC chemical subgroup (A10BB *glibenclamide not suitable above 60 years. 
Sulfonylureas) 

metformin Tablet: 500 mg (hydrochloride). 

Complementary List  

metformin [c] Tablet: 500 mg (hydrochloride). 

18.6 Medicines for hypoglycaemia 

glucagon Injection: 1 mg/mL. 

Complementary List  

Oral liquid: 50 mg/mL. 
diazoxide [c] 

Tablet: 50 mg. 

18.7 Thyroid hormones and antithyroid medicines 

Tablet: 25 micrograms [c]; 50 micrograms; 100 micrograms 
levothyroxine 

(sodium salt). 

potassium iodide Tablet: 60 mg. 

 methimazole 
Tablet: 5mg, 10mg, 20mg. 

Therapeutic alternatives: 

- carbimazole (depending on local availability) 

Tablet: 50 mg. 

propylthiouracil* *For use when alternative first-line treatment is not appropriate or 
available; and in patients during the first trimester of pregnancy.  

 WHO Model List of Essential Medicines – 23rd List (2023) page 47 



WHO Model List of Essential Medicines – 23rd List (2023)  

Complementary List  

Lugol's solution [c] Oral liquid: about 130 mg total iodine/mL. 

 methimazole [c] 

Therapeutic alternatives: Tablet: 5mg, 10mg, 20mg. 

- carbimazole (depending on local availability) 

potassium iodide  [c] Tablet: 60 mg. 

Tablet: 50 mg. 

propylthiouracil* [c] *For use when alternative first-line treatment is not appropriate or 
available  

18.8 Medicines for disorders of the pituitary hormone system 

 cabergoline 

Therapeutic alternatives: Tablet: 0.5 mg; 1 mg. 

- bromocriptine 

Complementary List  

Injection (immediate-release): 0.05 mg/mL; 0.1 mg/mL; 
0.5 mg/mL (as acetate) in 1 mL vial. 

octreotide 
Injection (modified-release): 20 mg (as acetate) in vial plus 
diluent. 

19. IMMUNOLOGICALS 

19.1 Diagnostic agents 

All tuberculins should comply with the WHO requirements for tuberculins.  

tuberculin, purified protein derivative (PPD) Injection. 

19.2 Sera, immunoglobulins and monoclonal antibodies 

All plasma fractions should comply with the WHO requirements. 

Injection: 40 IU/mL in 1.25 mL, 2.5 mL vial; 100 IU/mL in 2.5 mL 
anti-rabies virus monoclonal antibodies* vial (human). 

*including quality-assured biosimilars Injection: 300 IU/mL in 10 mL vial; 600 IU/mL in 1 mL, 2.5 mL and 
5 mL vial (murine). 

Injection. 
antivenom immunoglobulin* 

*Exact type to be defined locally. 

diphtheria antitoxin Injection: 10 000 IU; 20 000 IU in vial. 

equine rabies immunoglobulin Injection: 150 IU/mL; 200 IU/mL; 300 IU/mL; 400 IU/mL in vial. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 48 



WHO Model List of Essential Medicines – 23rd List (2023)  

19.3 Vaccines 

WHO immunization policy recommendations are published in vaccine position papers based on recommendations made by the 
Strategic Advisory Group of Experts on Immunization (SAGE).  

WHO vaccine position papers are updated three to four times per year. The list below details the vaccines for which there is a 
recommendation from SAGE and a corresponding WHO position paper as at March 2023. The most recent versions of the WHO 
position papers, reflecting the current evidence related to a specific vaccine and the related recommendations, can be accessed at 
any time on the WHO website at: 

https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers  

Vaccine recommendations may be universal or conditional (e.g., in certain regions, in some high-risk populations or as part of 
immunization programmes with certain characteristics). Details are available in the relevant position papers, and in the Summary Tables 
of WHO Routine Immunization Recommendations available on the WHO website at: 

https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/who-recommendations-for-routine-immunization---
summary-tables  

Selection of vaccines from the Model List will need to be determined by each country after consideration of international 
recommendations, epidemiology and national priorities.  

All vaccines should comply with the WHO requirements for biological substances.  

WHO noted the need for vaccines used in children to be polyvalent. 

Recommendations for all  

BCG vaccine  

diphtheria vaccine  

Haemophilus influenzae type b vaccine  

hepatitis B vaccine  

human papilloma virus (HPV) vaccine  

measles vaccine  

pertussis vaccine  

pneumococcal vaccine  

poliomyelitis vaccine   

rotavirus vaccine  

rubella vaccine   

tetanus vaccine   

  

Recommendations for certain regions  

Japanese encephalitis vaccine  

tick-borne encephalitis vaccine  

yellow fever vaccine  

  

Recommendations for some high-risk populations 

cholera vaccine  

dengue vaccine  

hepatitis A vaccine  

meningococcal meningitis vaccine  

 WHO Model List of Essential Medicines – 23rd List (2023) page 49 



WHO Model List of Essential Medicines – 23rd List (2023)  

rabies vaccine   

typhoid vaccine   

Recommendations for immunization programmes with certain characteristics 

influenza vaccine (seasonal)  

mumps vaccine   

varicella vaccine  

20. MUSCLE RELAXANTS (PERIPHERALLY-ACTING) AND CHOLINESTERASE INHIBITORS 

 atracurium  
Injection: 10 mg/mL (besylate). 

Therapeutic alternatives to be reviewed 

Injection: 500 micrograms/mL (methylsulfate) in 1 mL ampoule; 

neostigmine 2.5 mg/mL (methylsulfate) in 1 mL ampoule. 

Tablet: 15 mg (bromide). 

Injection: 50 mg/mL (chloride) in 2 mL ampoule. 
suxamethonium 

Powder for injection: (chloride), in vial. 

 vecuronium [c] 

Therapeutic alternatives: Powder for injection: 10 mg (bromide) in vial. 

-atracurium 

Complementary List 

Injection: 1 mg in 1 mL ampoule. 
pyridostigmine 

Tablet: 60 mg (bromide). 

 vecuronium 
Powder for injection: 10 mg (bromide) in vial. 

Therapeutic alternatives to be reviewed 

21. OPHTHALMOLOGICAL PREPARATIONS 

21.1 Anti-infective agents 

aciclovir Ointment: 3% w/w. 

Solution (eye drops): 1.5%. 
azithromycin 

− Trachoma 

Ointment: 0.5% [c] 

erythromycin − Infections due to Chlamydia trachomatis or Neisseria 
gonorrhoea. 

 gentamicin 

Therapeutic alternatives: Solution (eye drops): 0.3% (sulfate). 

- amikacin − Bacterial blepharitis  
- kanamycin − Bacterial conjunctivitis 
- netilmicin  
- tobramycin 

Suspension (eye drops): 5% 
natamycin 

− Fungal keratitis 

 WHO Model List of Essential Medicines – 23rd List (2023) page 50 



WHO Model List of Essential Medicines – 23rd List (2023)  

 ofloxacin 
Solution (eye drops): 0.3%. 

Therapeutic alternatives: 
− Bacterial conjunctivitis 

- 4th level ATC chemical subgroup (S01AE − Bacterial keratitis 
Fluoroquinolones) 

Eye ointment: 1% (hydrochloride). 
 tetracycline 

− Bacterial blepharitis 
Therapeutic alternatives: 

− Bacterial conjunctivitis 
- chlortetracycline − Bacterial keratitis 
- oxytetracycline − Trachoma 

21.2 Anti-inflammatory agents 

 prednisolone 
Solution (eye drops): 0.5% (sodium phosphate). 

Therapeutic alternatives to be reviewed  

21.3 Local anaesthetics 

 tetracaine a  
Solution (eye drops): 0.5% (hydrochloride). 

Therapeutic alternatives: 

- 4th level ATC chemical subgroup (S01HA Local a Not in preterm neonates. 

anaesthetics) excluding cocaine and combinations 

21.4 Miotics and antiglaucoma medicines 

acetazolamide Tablet: 250 mg. 

latanoprost  Solution (eye drops): 50 micrograms/mL. 

 pilocarpine 

Therapeutic alternatives: Solution (eye drops): 2%; 4% (hydrochloride or nitrate). 

- carbachol 

 timolol 

Therapeutic alternatives: 
Solution (eye drops): 0.25%; 0.5% (as hydrogen maleate). 

- 4th level ATC chemical subgroup (S01ED Beta blocking 
agents) excluding combinations 

21.5 Mydriatics 

 atropine a  

Therapeutic alternatives*: Solution (eye drops): 0.1%; 0.5%; 1% (sulfate). 

- cyclopentolate hydrochloride 
a > 3 months. 

- homatropine hydrobromide 

*EMLc only 

Complementary List 

epinephrine (adrenaline) Solution (eye drops): 2% (as hydrochloride). 

21.6 Anti-vascular endothelial growth factor (VEGF) preparations 

Complementary List 

bevacizumab* 
Injection: 25 mg/mL. 

*including quality-assured biosimilars 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 51 



WHO Model List of Essential Medicines – 23rd List (2023)  

22. MEDICINES FOR REPRODUCTIVE HEALTH AND PERINATAL CARE 

22.1 Contraceptives 

22.1.1 Oral hormonal contraceptives 

 ethinylestradiol +  levonorgestrel  
Tablet: 30 micrograms + 150 micrograms. 

Therapeutic alternatives to be reviewed  

 ethinylestradiol +  norethisterone  
Tablet: 35 micrograms + 1 mg. 

Therapeutic alternatives to be reviewed  

levonorgestrel Tablet: 30 micrograms; 750 micrograms (pack of two); 1.5 mg. 

ulipristal  Tablet: 30 mg (as acetate). 

22.1.2 Injectable hormonal contraceptives 

estradiol cypionate + medroxyprogesterone 
Injection: 5 mg + 25 mg. 

acetate  

Injection (intramuscular): 150 mg mL in 1 mL vial. 

medroxyprogesterone acetate Injection (subcutaneous): 104 mg/0.65 mL in pre-filled syringe or 
single-dose injection delivery system. 

norethisterone enantate Oily solution: 200 mg/mL in 1 mL ampoule. 

22.1.3 Intrauterine devices 

copper-containing device  

Intrauterine system: with reservoir containing 52 mg of 
levonorgestrel-releasing intrauterine system 

levonorestrel 

22.1.4 Barrier methods 

condoms  

diaphragms  

22.1.5 Implantable contraceptives 

Single-rod etonogestrel-releasing implant: containing 68 mg of 
etonogestrel-releasing implant 

etonogestrel. 

Two-rod levonorgestrel-releasing implant: each rod containing 
levonorgestrel-releasing implant 

75 mg of levonorgestrel (150 mg total). 

22.1.6 Intravaginal contraceptives 

ethinylestradiol + etonogestrel Vaginal ring: containing 2.7 mg + 11.7 mg  

Progesterone-releasing vaginal ring: containing 2.074 g of 

progesterone vaginal ring* micronized progesterone. 

*For use in women actively breastfeeding at least 4 times per day  

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 52 



WHO Model List of Essential Medicines – 23rd List (2023)  

22.2 Ovulation inducers 

Complementary List 

clomifene Tablet: 50 mg (citrate). 

 letrozole 

Therapeutic alternatives: Solid oral dosage form: 2.5 mg. 

- anastrozole 

22.3 Uterotonics 

carbetocin Injection (heat stable): 100 micrograms/mL. 

 ergometrine 

Therapeutic alternatives: Injection: 200 micrograms (hydrogen maleate) in 1 mL ampoule.  

- methylergometrine 

Tablet 200 mg – tablet 200 micrograms. 

mifepristone – misoprostol Co-package containing:  

Where permitted under national law and mifepristone 200 mg tablet [1] and misoprostol 200 micrograms 
where culturally acceptable. tablet [4] 

 − Management of intrauterine fetal demise; 
− Management of induced abortion 

Tablet: 200 micrograms. 
− Management of incomplete abortion and miscarriage; 
− Prevention and treatment of postpartum haemorrhage 

where oxytocin is not available or cannot be safely used 
misoprostol 

Vaginal tablet: 25 micrograms.* 

*Only for use for induction of labour where appropriate facilities 
are available. 

oxytocin Injection: 10 IU in 1 mL. 

22.4 Antioxytocics (tocolytics) 

nifedipine Immediate-release capsule: 10 mg. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 53 



WHO Model List of Essential Medicines – 23rd List (2023)  

22.5 Other medicines administered to the mother 

dexamethasone Injection: 4 mg/mL (as disodium phosphate salt) in 1 mL ampoule. 

Tablet containing:  

Vitamin A (retinol acetate) 800 micrograms retinol activity 
equivalent 

Vitamin C (ascorbic acid) 70 mg 
Vitamin D (cholecalciferol) 5 micrograms (200 IU) 
Vitamin E (alpha tocopherol 10 mg alpha tocopherol equivalent 
succinate) 
Vitamin B1 (thiamine mononitrate) 1.4 mg 
Vitamin B2 (riboflavin) 1.4 mg 
Vitamin B3 (niacinamide) 18 mg niacin equivalent 
Vitamin B6 (pyridoxine 1.9 mg 

multiple micronutrient supplement* hydrochloride) 
Folic acid (folic acid) 680 micrograms dietary folate 

equivalent (400 micrograms) 
Vitamin B12 (cyanocobalamin) 2.6 micrograms 
Iron (ferrous fumarate) 30 mg 
Iodine (potassium iodide) 150 micrograms 
Zinc (zinc oxide) 15 mg 
Selenium (sodium selenite) 65 micrograms 
Copper (cupric oxide)  2 mg 

 

*For use in specific contexts. Refer to current WHO 
recommendations. 

tranexamic acid  Injection: 100 mg/mL in 10 mL ampoule. 

22.6 Medicines administered to the neonate [c] 

Injection: 20 mg/mL (equivalent to 10 mg caffeine base/mL). 
caffeine citrate [c] 

Oral liquid: 20 mg/mL (equivalent to 10 mg caffeine base/mL). 

Solution or gel: 7.1% (digluconate) delivering 4% chlorhexidine (for 
chlorhexidine [c] 

umbilical cord care).  

Complementary List 

 ibuprofen [c] 

Therapeutic alternatives: Solution for injection: 5 mg/mL. 

- indometacin 

 prostaglandin E1 [c] 

Therapeutic alternatives: Solution for injection: 0.5 mg/mL in alcohol. 

- prostaglandin E2 

surfactant [c] Suspension for intratracheal instillation: 25 mg/mL or 80 mg/mL. 

23. PERITONEAL DIALYSIS SOLUTION 

Complementary List 

intraperitoneal dialysis solution Parenteral solution: of appropriate composition. 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 54 



WHO Model List of Essential Medicines – 23rd List (2023)  

24. MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS 

24.1 Medicines for psychotic disorders 

 fluphenazine 

Therapeutic alternatives: Injection: 25 mg (decanoate or enantate) in 1 mL ampoule. 
- haloperidol decanonate 
- zuclopenthixol decanonate 

 haloperidol 

Therapeutic alternatives: Tablet: 2 mg; 5 mg. 

- chlorpromazine 

haloperidol Injection: 5 mg/mL in 1 mL ampoule. 

olanzapine Powder for injection: 10 mg in vial. 

 paliperidone 
Injection (prolonged-release): 25 mg; 50 mg; 75 mg; 100 mg; 

Therapeutic alternatives: 
150 mg (as palmitate) in pre-filled syringe. 

- risperidone injection  

 risperidone  

Therapeutic alternatives: 

- aripiprazole Solid oral dosage form: 0.25 mg to 6.0 mg. 
- olanzapine 
- paliperidone 
- quetiapine 
 

Complementary List 

clozapine Solid oral dosage form: 25 to 200 mg. 

24.2 Medicines for mood disorders 

24.2.1 Medicines for depressive disorders 

amitriptyline Tablet: 25 mg; 75mg (hydrochloride).  

 fluoxetine 

Therapeutic alternatives: 

- citalopram 
Solid oral dosage form: 20 mg (as hydrochloride). 

- escitalopram 
- fluvoxamine 
- paroxetine 
- sertraline 
 

24.2.2 Medicines for bipolar disorders 

carbamazepine Tablet (scored): 100 mg; 200 mg; 400 mg. 

lithium carbonate Solid oral dosage form: 300 mg. 

 quetiapine 
Tablet (immediate-release): 25 mg; 100 mg; 150 mg; 200 mg; 

Therapeutic alternatives: 300 mg. 

- aripiprazole Tablet (modified-release): 50 mg; 150 mg; 200 mg; 300 mg; 
- olanzapine 

400 mg. 
- paliperidone 
 

 WHO Model List of Essential Medicines – 23rd List (2023) page 55 



WHO Model List of Essential Medicines – 23rd List (2023)  

valproic acid (sodium valproate)* 

*avoid use in pregnancy and in women and girls of child-
bearing potential, unless alternative treatments are Tablet (enteric-coated): 200 mg; 500 mg. 
ineffective or not tolerated because of the high risk of 
birth defects and developmental disorders in children 
exposed to valproate in the womb. 

24.3 Medicines for anxiety disorders  

Tablet (scored): 2 mg; 5 mg. 
 diazepam* 

Therapeutic alternatives: *For short-term emergency management of acute and severe 

- lorazepam  anxiety symptoms only 

 fluoxetine 

Therapeutic alternatives: 

- citalopram 
Solid oral dosage form: 20 mg (as hydrochloride). 

- escitalopram 
- fluvoxamine 
- paroxetine 
- sertraline 
 

24.4 Medicines for obsessive compulsive disorders 

clomipramine Capsule: 10 mg; 25 mg (hydrochloride). 

 fluoxetine 

Therapeutic alternatives: 

- citalopram 
Solid oral dosage form: 20 mg (as hydrochloride). 

- escitalopram 
- fluvoxamine 
- paroxetine 
- sertraline 
 

24.5 Medicines for disorders due to psychoactive substance use 

24.5.1 Medicines for alcohol use disorders 

acamprosate calcium Tablet: 333 mg 

Injection suspension (extended-release): 380 mg in vial 
naltrexone 

Tablet: 50 mg 

24.5.2 Medicines for nicotine use disorders 

bupropion  Tablet (sustained-release): 150 mg (hydrochloride). 

Chewing gum: 2 mg; 4 mg (as polacrilex). 

Lozenge: 2 mg; 4 mg. 
nicotine replacement therapy (NRT)  

Oral spray: 1 mg per actuation. 

Transdermal patch: 5 mg to 30 mg/16 hrs; 7 mg to 21 mg/24 hrs. 

varenicline Tablet: 0.5 mg, 1 mg 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 56 



WHO Model List of Essential Medicines – 23rd List (2023)  

24.5.3 Medicines for opioid use disorders 

Complementary List 

Concentrate for oral liquid: 5 mg/mL; 10 mg/mL (hydrochloride). 
 methadone* 

Oral liquid: 5 mg/5 mL; 10 mg/5 mL (hydrochloride). 
Therapeutic alternatives: 

*The medicines should only be used within an established support 
- buprenorphine 

programme. 

25. MEDICINES ACTING ON THE RESPIRATORY TRACT 

25.1 Antiasthmatic medicines and medicines for chronic obstructive pulmonary disease 

 budesonide  

Therapeutic alternatives: 

- beclometasone Inhalation (aerosol): 100 micrograms per dose; 200 micrograms 
- ciclesonide  

per dose. 
- flunisolide 
- fluticasone 
- mometasone 
 

 budesonide +  formoterol 

Therapeutic alternatives: 

- beclometasone + formoterol  Dry powder inhaler: 100 micrograms + 6 micrograms per dose; 
- budesonide + salmeterol 200 micrograms + 6 micrograms per dose. 
- fluticasone + formoterol 
- fluticasone furoate + vilanterol 
- mometasone + formoterol 
 

Injection: 1 mg/mL (as hydrochloride or hydrogen tartrate) in 
epinephrine (adrenaline) 

1 mL ampoule. 

ipratropium bromide Inhalation (aerosol): 20 micrograms/metered dose. 

Inhalation (aerosol): 100 micrograms (as sulfate) per dose. 
 salbutamol 

Injection: 50 micrograms/mL (as sulfate) in 5 mL ampoule. 
Therapeutic alternatives: 

Metered dose inhaler (aerosol): 100 micrograms (as sulfate) per 
- terbutaline dose. 
 

Respirator solution for use in nebulizers: 5 mg/mL (as sulfate). 

 tiotropium 

Therapeutic alternatives: Powder for inhalaton, capsule: 18 micrograms.  

- aclidinium Inhalation solution: 1.25 micrograms; 2.5 micrograms per 
- glycopyrronium actuation. 
- umeclidinium 
 

26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID–BASE DISTURBANCES 

26.1 Oral 

oral rehydration salts  See section 17.5.1.  

potassium chloride Powder for solution. 

26.2 Parenteral 

Injectable solution: 5% (isotonic); 10% (hypertonic); 
glucose 

50%  (hypertonic). 

 WHO Model List of Essential Medicines – 23rd List (2023) page 57 



WHO Model List of Essential Medicines – 23rd List (2023)  

Injectable solution: 4% glucose, 0.18% sodium chloride  
(equivalent to Na+ 30 mmol/L, Cl- 30 mmol/L). 

glucose with sodium chloride Injectable solution: 5% glucose, 0.9% sodium chloride (equivalent 
to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% glucose, 0.45% 
sodium chloride (equivalent to Na+ 75 mmol/L and Cl- 
75 mmol/L) [c]. 

Solution: 11.2% in 20 mL ampoule 
(equivalent to K+ 1.5 mmol/mL, Cl- 1.5 mmol/mL). 

potassium chloride Solution for dilution: 7.5% (equivalent to K 1 mmol/mL and Cl 
1 mmol/mL) [c]; 15% (equivalent to K 2 mmol/mL and Cl 
2 mmol/mL) [c]. 

Injectable solution: 0.9% isotonic (equivalent to Na+ 154 mmol/L, 
sodium chloride 

Cl- 154 mmol/L). 

Injectable solution: 1.4% isotonic (equivalent to Na+ 167 mmol/L, 
HCO3- 167 mmol/L). 

sodium hydrogen carbonate 
Solution: 8.4% in 10 mL ampoule (equivalent to Na+ 

1000 mmol/L, HCO3-1000 mmol/L). 

sodium lactate, compound solution Injectable solution. 

26.3 Miscellaneous 

water for injection 2 mL; 5 mL; 10 mL ampoules. 

27. VITAMINS AND MINERALS 

ascorbic acid Tablet: 50 mg. 

calcium Tablet: 500 mg (elemental). 

 colecalciferol [c] 
Oral liquid: 400 IU/mL. 

Therapeutic alternatives: 
Solid oral dosage form: 400 IU; 1000 IU. 

- ergocalciferol 
 ergocalciferol 

Oral liquid: 250 micrograms/mL (10 000 IU/mL). 
Therapeutic alternatives: 

Solid oral dosage form: 1.25 mg (50 000 IU). 
- colecalciferol 
 

Capsule: 190 mg. 

iodine  Iodized oil: 1 mL (480 mg iodine); 0.5 mL (240 mg iodine) in 
ampoule (oral or injectable); 0.57 mL (308 mg iodine) in 
dispenser bottle. 

Sachets containing: 

- iron (elemental) 12.5 mg (as coated ferrous fumarate) 

- zinc (elemental) 5 mg 
multiple micronutrient powder [c] 

- vitamin A 300 micrograms 

- with or without other micronutrients at recommended daily 
values 

nicotinamide Tablet: 50 mg. 

pyridoxine Tablet: 25 mg (hydrochloride). 

 WHO Model List of Essential Medicines – 23rd List (2023) page 58 



WHO Model List of Essential Medicines – 23rd List (2023)  

Capsule: 50 000 IU; 100 000 IU; 200 000 IU (as palmitate). 

Oral oily solution: 100 000 IU/mL (as palmitate) in multidose 
dispenser. 

retinol 
Tablet (sugar-coated): 10 000 IU (as palmitate). 

Water-miscible injection: 100 000 IU (as palmitate) in  
2 mL ampoule. 

riboflavin Tablet: 5 mg. 

thiamine Tablet: 50 mg (hydrochloride). 

Complementary List 

calcium gluconate Injection: 100 mg/mL in 10 mL ampoule. 

28. EAR, NOSE AND THROAT MEDICINES  

acetic acid [c] Topical: 2%, in alcohol. 

 budesonide  [c] 
 Nasal spray: 100 micrograms per dose. 

Therapeutic alternatives to be reviewed  

 ciprofloxacin [c] 

Therapeutic alternatives: Solution (ear drops): 0.3% (as hydrochloride). 

- ofloxacin 

 xylometazoline a  [c] Nasal spray: 0.05%.  
 

a Not in children less than 3 months. 
Therapeutic alternatives to be reviewed  

29. MEDICINES FOR DISEASES OF JOINTS  

29.1 Medicines used to treat gout 

allopurinol Tablet: 100 mg. 

29.2 Disease-modifying anti-rheumatic drugs (DMARDs) 

chloroquine Tablet: 100 mg; 150 mg (as phosphate or sulfate). 

Complementary List 

azathioprine Tablet: 50 mg. 

hydroxychloroquine  Solid oral dosage form: 200 mg (as sulfate). 

methotrexate Tablet: 2.5 mg (as sodium). 

penicillamine Solid oral dosage form: 250 mg. 

sulfasalazine Tablet: 500 mg. 

29.3 Medicines for juvenile joint diseases 

Complementary List 

Suppository: 50 mg to 150 mg. 

acetylsalicylic acid* (acute or chronic use) Tablet: 100 mg to 500 mg. 

*For use for rheumatic fever, juvenile arthritis, Kawasaki disease. 

 WHO Model List of Essential Medicines – 23rd List (2023) page 59 



WHO Model List of Essential Medicines – 23rd List (2023)  

o adalimumab* 

Therapeutic alternatives*:  

- certolizumab pegol Injection: 10 mg/0.2 mL [c]; 20 mg/0.4 mL [c]; 40 mg/0.8 mL; 
- etanercept 40 mg/0.4 mL. 
- golimumab 
- infliximab 

 *including quality-assured biosimilars 

methotrexate Tablet: 2.5 mg (as sodium). 

 triamcinolone hexacetonide 

Therapeutic alternatives: Injection: 20 mg/mL in vial. 

- triamcinolone acetonide 

30. DENTAL MEDICINES AND PREPARATIONS  

Gel: containing 2500 to 12 500 ppm fluoride (any type). 

Mouthrinse: containing 230 to 900 ppm fluoride (any type). 

fluoride Toothpaste, cream or gel: containing 1000 to 1500 ppm fluoride 
(any type). 

Varnish: containing 22 500 ppm fluoride (any type). 

Single-use capsules: 0.4 g powder + 0.09 mL liquid. 

Multi-use bottle: powder + liquid. 

glass ionomer cement Powder (fluoro-alumino-silicate glass) contains: 25-50% silicate, 20-40% 
aluminium oxide, 1-20% fluoride, 15-40% metal oxide, 0-15% 
phosphate, remainder are polyacrylic acid powder and metals in minimal 
quantities. Liquid (aqueous) contains: 7-25% polybasic carboxylic acid, 
45-60% polyacrylic acid. 

Single-use applicator or multi-use bottle 
resin-based composite (low-viscosity)* 

*of any type for use as dental sealant 

Single-use capsule or multi-use syringe 
resin-based composite (high-viscosity)* 

*of any type for use as dental filling material 

silver diamine fluoride Solution: 38% w/v. 

 
 

  

 WHO Model List of Essential Medicines – 23rd List (2023) page 60 



WHO Model List of Essential Medicines – 23rd List (2023)  

Table 1.1: Medicines with age or weight restrictions 
 

artesunate + pyronaridine tetraphosphate > 5 kg 
atropine > 3 months 
benzyl benzoate >2 years 
betamethasone topical preparations hydrocortisone preferred in neonates 
cefazolin > 1 month 
ceftriaxone > 41 weeks corrected gestational age 
darunavir > 3 years 
dihydroartemisinin + piperaquine phosphate > 5 kg 
diloxanide >25 kg  
dolutegravir ≥ 4 weeks and ≥ 3 kg (10 mg dispersible tablet) 

≥ 25 kg (50 mg tablet) 
doxycycline > 8 years (except for serious infections e.g. cholera) 
ibuprofen > 3 months (except IV form for patent ductus arteriosus) 
mefloquine > 5 kg or > 3 months 
metoclopramide Not in neonates 
nevirapine > 6 weeks 
ondansetron > 1 month 
silver sulfadiazine > 2 months 
tetracaine Not in preterm neonates 
xylometazoline > 3 months 

 

 WHO Model List of Essential Medicines – 23rd List (2023) page 61 



WHO Model List of Essential Medicines – 23rd List (2023)  

Table 1.2: Explanation of dosage forms 
 

A. Principal dosage forms used in EML – oral administration 
 

  
Term Definition 

  
Refers to tablets or capsules or other solid dosage forms such as 'melts' 
that are immediate-release preparations. It implies that there is no 
difference in clinical efficacy or safety between the available dosage forms, 
and countries should therefore choose the form(s) to be listed depending 

Solid oral dosage form on quality and availability.  
 
The term 'solid oral dosage form' is never intended to allow any type of 
modified-release tablet. 
 
Refers to:  
 
• uncoated or coated (film-coated or sugar-coated) tablets that are 

intended to be swallowed whole;  

• unscored and scored*;  
• tablets that are intended to be chewed before being swallowed;  

Tablets  • tablets that are intended to be dispersed or dissolved in water or 
another suitable liquid before being swallowed;  

• tablets that are intended to be crushed before being swallowed. 
 
The term 'tablet' without qualification is never intended to allow any type of 
modified-release tablet. 
 
Refers to a specific type of tablet: 
chewable - tablets that are intended to be chewed before being swallowed;  
dispersible - tablets that are intended to be dispersed in water or another 
suitable liquid before being swallowed;  
soluble - tablets that are intended to be dissolved in water or another 
suitable liquid before being swallowed;  
crushable - tablets that are intended to be crushed before being 
swallowed;  

Tablets (qualified) 
scored - tablets bearing a break mark or marks where sub-division is 
intended in order to provide doses of less than one tablet; 
sublingual - tablets that are intended to be placed beneath the tongue. 
 
The term 'tablet' is always qualified with an additional term (in parentheses) 
in entries where one of the following types of tablet is intended: gastro-
resistant (such tablets may sometimes be described as enteric-coated or 
as delayed-release), prolonged-release or another modified-release form. 

  

 
* Scored tablets may be divided for ease of swallowing, provided that dose is a whole number of tablets. 

 WHO Model List of Essential Medicines – 23rd List (2023) page 62 



WHO Model List of Essential Medicines – 23rd List (2023)  

Refers to hard or soft capsules.  
 

Capsules  The term 'capsule' without qualification is never intended to allow any type 
of modified-release capsule. 
 
The term 'capsule' with qualification refers to gastro-resistant (such 
capsules may sometimes be described as enteric-coated or as delayed-

Capsules (qualified) 
release), prolonged-release or another modified-release form. 
 
Preparations that are issued to patient as granules to be swallowed without 
further preparation, to be chewed, or to be taken in or with water or 
another suitable liquid. 

Granules  
The term 'granules' without further qualification is never intended to allow 
any type of modified-release granules. 
 
Preparations that are issued to patient as powder (usually as single-dose) 

Oral powder to be taken in or with water or another suitable liquid. 
 
Liquid preparations intended to be swallowed i.e. oral solutions, 
suspensions, emulsions and oral drops, including those constituted from 
powders or granules, but not those preparations intended for oromucosal 
administration e.g. gargles and mouthwashes. 
 
Oral liquids presented as powders or granules may offer benefits in the 

Oral liquid  
form of better stability and lower transport costs. If more than one type of 
oral liquid is available on the same market (e.g. solution, suspension, 
granules for reconstitution), they may be interchanged and in such cases 
should be bioequivalent. It is preferable that oral liquids do not contain 
sugar and that solutions for children do not contain alcohol. 
 

 
B. Principal dosage forms used in EML – parenteral administration 

 
Term Definition 

Injection Refers to solutions, suspensions and emulsions including those constituted 
from powders or concentrated solutions. 

Injection (qualified) Route of administration is indicated in parentheses where relevant. 
Injection (oily) The term `injection’ is qualified by `(oily)’ in relevant entries. 
Intravenous infusion Refers to solutions and emulsions including those constituted from powders 

or concentrated solutions. 
 

C. Other dosage forms 
 

Mode of administration Term to be used 
To the eye Eye drops, eye ointments. 
Topical For liquids: lotions, paints. 

For semi-solids: cream, ointment. 
Rectal  Suppositories, gel or solution. 
Vaginal Pessaries or vaginal tablets. 
Inhalation Powder for inhalation, pressurized inhalation, nebulizer. 

 

 WHO Model List of Essential Medicines – 23rd List (2023) page 63 



WHO Model List of Essential Medicines – 23rd List (2023)  

Index 

abacavir ...................................................................... 19 betamethasone............................................................ 42 
abacavir + lamivudine .................................................. 20 bevacizumab ............................................................... 51 
abiraterone .................................................................. 33 bicalutamide ................................................................ 33 
acamprosate calcium .................................................. 56 biperiden ....................................................................... 6 
acetazolamide ............................................................. 51 bisoprolol ......................................................... 37, 38, 40 
acetic acid ................................................................... 59 bleomycin .................................................................... 27 
acetylcysteine ................................................................ 4 bortezomib .................................................................. 32 
acetylsalicylic acid ....................................... 2, 26, 40, 59 budesonide ........................................................... 57, 59 
acetylsalicylic acid + atorvastatin + ramipril .................. 41 budesonide + formoterol .............................................. 57 
acetylsalicylic acid + simvastatin + ramipril + atenolol + bupivacaine ................................................................... 1 

hydrochlorothiazide .................................................. 41 bupropion .................................................................... 56 
aciclovir ................................................................. 19, 50 cabergoline ................................................................. 48 
adalimumab........................................................... 26, 60 caffeine citrate ............................................................. 54 
albendazole ................................................................... 7 calamine ...................................................................... 42 
alcohol based hand rub ............................................... 43 calcipotriol ................................................................... 42 
allopurinol .............................................................. 34, 59 calcium ....................................................................... 58 
all-trans retinoid acid (ATRA) ....................................... 32 calcium folinate (leucovorin calcium) ............................ 27 
alteplase ...................................................................... 40 calcium gluconate ................................................... 4, 59 
amidotrizoate ............................................................... 43 capecitabine ................................................................ 27 
amikacin .................................................................. 9, 17 carbamazepine ........................................................ 5, 55 
amiloride ..................................................................... 44 carbetocin ................................................................... 53 
amiodarone ................................................................. 38 carboplatin .................................................................. 27 
amitriptyline ............................................................. 3, 55 cefalexin ...................................................................... 10 
amlodipine ................................................................... 38 cefazolin ...................................................................... 10 
amodiaquine ................................................................ 22 cefiderocol .................................................................. 15 
amodiaquine – sulfadoxine + pyrimethamine ................ 24 cefixime ....................................................................... 13 
amoxicillin...................................................................... 9 cefotaxime ................................................................... 13 
amoxicillin + clavulanic acid ..................................... 9, 17 ceftazidime .................................................................. 15 
amphotericin B ...................................................... 18, 22 ceftazidime + avibactam .............................................. 15 
ampicillin ..................................................................... 10 ceftolozane + tazobactam ............................................ 15 
anastrozole .................................................................. 33 ceftriaxone .................................................................. 14 
ansuvimab ................................................................... 25 cefuroxime .................................................................. 14 
anti-D immunoglobulin ................................................. 37 charcoal, activated ........................................................ 4 
anti-rabies immunoglobulin .......................................... 37 chlorambucil ................................................................ 27 
anti-rabies virus monoclonal antibodies ........................ 48 chloramphenicol .......................................................... 10 
anti-tetanus immunoglobulin ........................................ 37 chlorhexidine ......................................................... 43, 54 
antivenom immunoglobulin .......................................... 48 chlorine base compound.............................................. 43 
aprepitant .................................................................... 45 chloroquine ..................................................... 23, 24, 59 
arsenic trioxide ............................................................ 27 chloroxylenol ............................................................... 44 
artemether .................................................................. 22 cholera vaccine ........................................................... 49 
artemether + lumefantrine ............................................ 22 ciclosporin ................................................................... 26 
artesunate ................................................................... 23 ciprofloxacin .......................................................... 14, 59 
artesunate + amodiaquine ........................................... 23 cisplatin ....................................................................... 28 
artesunate + mefloquine .............................................. 23 cladribine ...................................................................... 6 
artesunate + pyronaridine tetraphosphate .................... 23 clarithromycin .............................................................. 14 
ascorbic acid ............................................................... 58 clindamycin ................................................................. 11 
asparaginase ............................................................... 27 clofazimine ............................................................ 16, 17 
atazanavir + ritonavir ................................................... 19 clomifene ..................................................................... 53 
atoltivimab + maftivimab + odesivimab ......................... 25 clomipramine ............................................................... 56 
atorvastatin + perindopril + amlodipine ......................... 41 clopidogrel .................................................................. 40 
atracurium ................................................................... 50 clotrimazole ................................................................. 18 
atropine ............................................................... 1, 4, 51 cloxacillin ..................................................................... 11 
azathioprine ........................................................... 26, 59 clozapine ..................................................................... 55 
azithromycin .......................................................... 13, 50 coagulation factor IX .................................................... 37 
barium sulfate .............................................................. 43 coagulation factor VIII .................................................. 37 
BCG vaccine ............................................................... 49 coal tar ........................................................................ 42 
bedaquiline .................................................................. 17 codeine ......................................................................... 2 
bendamustine .............................................................. 27 colecalciferol ............................................................... 58 
benzathine benzylpenicillin ........................................... 10 colistin ......................................................................... 15 
benznidazole ............................................................... 25 condoms ..................................................................... 52 
benzoyl peroxide ......................................................... 42 copper-containing device............................................. 52 
benzyl benzoate .......................................................... 42 cryoprecipitate, pathogen-reduced .............................. 36 
benzylpenicillin ............................................................ 10 cyclizine ........................................................................ 3 

 WHO Model List of Essential Medicines – 23rd List (2023) page 64 



WHO Model List of Essential Medicines – 23rd List (2023)  

cyclophosphamide....................................................... 28 fentanyl ......................................................................... 2 
cycloserine .................................................................. 17 ferrous salt .................................................................. 35 
cytarabine ................................................................... 28 ferrous salt + folic acid ................................................. 35 
dabigatran ................................................................... 35 fexinidazole ................................................................. 24 
dacarbazine ................................................................ 28 filgrastim ...................................................................... 33 
daclatasvir ................................................................... 21 fluconazole .................................................................. 18 
daclatasvir + sofosbuvir ............................................... 21 flucytosine ................................................................... 18 
dactinomycin ............................................................... 28 fludarabine .................................................................. 29 
dapsone ...................................................................... 16 fludrocortisone............................................................. 46 
darunavir ..................................................................... 19 fluorescein ................................................................... 43 
dasatinib ..................................................................... 32 fluoride ........................................................................ 60 
daunorubicin ............................................................... 28 fluorouracil ............................................................ 29, 42 
deferasirox .................................................................. 36 fluoxetine ........................................................... 3, 55, 56 
deferoxamine .......................................................... 4, 36 fluphenazine ................................................................ 55 
delamanid ................................................................... 17 folic acid ...................................................................... 35 
dengue vaccine ........................................................... 49 fomepizole ..................................................................... 4 
desmopressin .............................................................. 36 fosfomycin ................................................................... 15 
dexamethasone ....................................... 3, 4, 34, 45, 54 fresh-frozen plasma ..................................................... 36 
dextran 70 ................................................................... 37 furosemide ............................................................ 40, 44 
diaphragms ................................................................. 52 gemcitabine ................................................................. 29 
diazepam ............................................................ 3, 5, 56 gentamicin............................................................. 11, 50 
diazoxide ..................................................................... 47 glass ionomer cement .................................................. 60 
diethylcarbamazine ........................................................ 7 glatiramer acetate.......................................................... 6 
digoxin .................................................................. 38, 40 glecaprevir + pibrentasvir ............................................. 21 
dihydroartemisinin + piperaquine phosphate ................ 23 gliclazide ..................................................................... 47 
diloxanide .................................................................... 22 glucagon ..................................................................... 47 
dimercaprol ................................................................... 4 glucose ....................................................................... 57 
diphtheria antitoxin ...................................................... 48 glucose with sodium chloride ....................................... 58 
diphtheria vaccine ....................................................... 49 glutaral ........................................................................ 44 
docetaxel .................................................................... 29 glyceryl trinitrate .......................................................... 37 
docusate sodium ........................................................... 3 griseofulvin .................................................................. 18 
dolutegravir ................................................................. 20 Haemophilus influenzae type b vaccine ........................ 49 
dolutegravir + lamivudine + tenofovir ............................ 20 haloperidol .............................................................. 3, 55 
dopamine .................................................................... 40 halothane ...................................................................... 1 
doxorubicin ................................................................. 29 heparin sodium ............................................................ 36 
doxorubicin (as pegylated liposomal) ........................... 29 hepatitis A vaccine ...................................................... 49 
doxycycline ..................................................... 11, 23, 24 hepatitis B vaccine ...................................................... 49 
efavirenz...................................................................... 19 human papilloma virus (HPV) vaccine .......................... 49 
efavirenz + emtricitabine + tenofovir ............................. 20 hydralazine .................................................................. 38 
efavirenz + lamivudine + tenofovir ................................ 20 hydrochlorothiazide ......................................... 38, 40, 44 
eflornithine................................................................... 25 hydrocortisone ...................................... 4, 34, 42, 45, 46 
empagliflozin ............................................................... 47 hydroxocobalamin ....................................................... 35 
emtricitabine + tenofovir .............................................. 20 hydroxycarbamide (hydroxyurea) ........................... 30, 36 
enalapril ................................................................ 38, 40 hydroxychloroquine ..................................................... 59 
enoxaparin .................................................................. 36 hyoscine butylbromide ................................................... 3 
entecavir ..................................................................... 21 hyoscine hydrobromide .................................................. 3 
ephedrine ...................................................................... 1 ibrutinib ....................................................................... 32 
epinephrine (adrenaline) .............................. 4, 38, 51, 57 ibuprofen ........................................................... 2, 26, 54 
equine rabies immunoglobulin ...................................... 48 ifosfamide .................................................................... 30 
ergocalciferol ............................................................... 58 imatinib ....................................................................... 32 
ergometrine ................................................................. 53 influenza vaccine ......................................................... 50 
erlotinib ....................................................................... 32 insulin injection (soluble) .............................................. 47 
erythromycin ............................................................... 50 intermediate-acting insulin ........................................... 47 
erythropoiesis-stimulating agents ................................. 35 intraperitoneal dialysis solution ..................................... 54 
estradiol cypionate + medroxyprogesterone acetate .... 52 iodine .......................................................................... 58 
ethambutol .................................................................. 16 iohexol......................................................................... 43 
ethambutol + isoniazid + pyrazinamide + rifampicin ...... 16 ipratropium bromide .................................................... 57 
ethambutol + isoniazid + rifampicin .............................. 16 irinotecan .................................................................... 30 
ethanol ........................................................................ 43 isoflurane ....................................................................... 1 
ethinylestradiol + etonogestrel ..................................... 52 isoniazid ...................................................................... 16 
ethinylestradiol + levonorgestrel ................................... 52 isoniazid + pyrazinamide + rifampicin ........................... 16 
ethinylestradiol + norethisterone .................................. 52 isoniazid + pyridoxine + sulfamethoxazole + trimethoprim20 
ethionamide........................................................... 16, 17 isoniazid + rifampicin.................................................... 16 
ethosuximide ................................................................. 6 isoniazid + rifapentine .................................................. 16 
etonogestrel-releasing implant ..................................... 52 isosorbide dinitrate ...................................................... 37 
etoposide .................................................................... 29 itraconazole ................................................................. 18 
everolimus ................................................................... 32 ivermectin................................................................ 7, 25 

 WHO Model List of Essential Medicines – 23rd List (2023) page 65 



WHO Model List of Essential Medicines – 23rd List (2023)  

Japanese encephalitis vaccine ..................................... 49 mupirocin .................................................................... 42 
ketamine ....................................................................... 1 naloxone ....................................................................... 4 
lactulose ........................................................................ 3 naltrexone ................................................................... 56 
lamivudine ................................................................... 19 natamycin.................................................................... 50 
lamivudine + zidovudine ............................................... 20 neostigmine ................................................................. 50 
lamotrigine .................................................................... 5 nevirapine.................................................................... 19 
latanoprost .................................................................. 51 niclosamide ................................................................... 7 
ledipasvir + sofosbuvir ................................................. 21 nicotinamide ................................................................ 58 
lenalidomide ................................................................ 33 nicotine replacement therapy (NRT) ............................. 56 
letrozole ...................................................................... 53 nifedipine ..................................................................... 53 
leuprorelin ................................................................... 34 nifurtimox .................................................................... 25 
levamisole ..................................................................... 7 nilotinib ........................................................................ 32 
levetiracetam ............................................................. 5, 6 nitrofurantoin ............................................................... 12 
levodopa + carbidopa .................................................... 6 nitrous oxide .................................................................. 1 
levofloxacin ................................................................. 17 nivolumab .................................................................... 33 
levonorgestrel .............................................................. 52 norethisterone enantate ............................................... 52 
levonorgestrel-releasing implant ................................... 52 normal immunoglobulin ................................................ 37 
levonorgestrel-releasing intrauterine system ................. 52 nystatin ....................................................................... 18 
levothyroxine ............................................................... 47 octreotide .................................................................... 48 
lidocaine .................................................................. 1, 38 ofloxacin ...................................................................... 51 
lidocaine + epinephrine (adrenaline)............................... 1 olanzapine ................................................................... 55 
linezolid ................................................................. 15, 17 omeprazole ................................................................. 44 
lisinopril + amlodipine ................................................... 39 ondansetron ............................................................ 3, 45 
lisinopril + hydrochlorothiazide ..................................... 39 oral rehydration salts ............................................. 46, 57 
lithium carbonate ......................................................... 55 oral rehydration salts – zinc sulfate ............................... 45 
long-acting insulin analogues ....................................... 47 oseltamivir ................................................................... 21 
loperamide .................................................................... 3 oxaliplatin .................................................................... 30 
lopinavir + ritonavir ...................................................... 19 oxamniquine .................................................................. 7 
loratadine ...................................................................... 4 oxygen ...................................................................... 1, 2 
lorazepam ..................................................................... 5 oxytocin ....................................................................... 53 
losartan ................................................................. 39, 40 paclitaxel ..................................................................... 31 
Lugol's solution ............................................................ 48 paliperidone................................................................. 55 
magnesium sulfate ......................................................... 5 p-aminosalicylate sodium ............................................. 17 
mannitol ...................................................................... 44 pancreatic enzymes ..................................................... 44 
measles vaccine .......................................................... 49 paracetamol (acetaminophen) ................................. 2, 26 
mebendazole ................................................................. 7 paromomycin .............................................................. 22 
medroxyprogesterone acetate ............................... 46, 52 pegaspargase ............................................................. 31 
mefloquine............................................................. 23, 24 pegfilgrastim ................................................................ 33 
meglumine antimoniate ................................................ 22 penicillamine............................................................ 4, 59 
meglumine iotroxate .................................................... 43 pentamidine................................................................. 24 
melarsoprol ................................................................. 25 permethrin ................................................................... 42 
melphalan ................................................................... 30 pertussis vaccine ......................................................... 49 
meningococcal meningitis vaccine ............................... 49 phenobarbital ................................................................ 5 
mercaptopurine ........................................................... 30 phenoxymethylpenicillin ............................................... 12 
meropenem ........................................................... 15, 17 phenytoin ...................................................................... 5 
meropenem + vaborbactam ......................................... 16 phytomenadione .......................................................... 36 
mesna ......................................................................... 34 pilocarpine ................................................................... 51 
metformin .................................................................... 47 piperacillin + tazobactam ............................................. 15 
methadone .............................................................. 2, 57 platelets ...................................................................... 36 
methimazole .......................................................... 47, 48 plazomicin ................................................................... 16 
methotrexate ................................................... 30, 42, 59 pneumococcal vaccine ................................................ 49 
methyldopa ................................................................. 39 podophyllum resin ....................................................... 42 
methylprednisolone ..................................................... 34 poliomyelitis vaccine .................................................... 49 
methylthioninium chloride (methylene blue) .................... 4 polymyxin B ................................................................. 16 
metoclopramide....................................................... 3, 45 potassium chloride................................................. 57, 58 
metronidazole ........................................................ 12, 22 potassium ferric hexacyano-ferrate(II) -2H2O ................. 4 
micafungin ................................................................... 18 potassium iodide ............................................. 18, 47, 48 
miconazole .................................................................. 41 potassium permanganate ............................................ 42 
midazolam ............................................................. 1, 3, 5 povidone iodine ........................................................... 43 
mifepristone – misoprostol ........................................... 53 praziquantel ................................................................... 7 
miltefosine ................................................................... 22 prednisolone ................................................ 4, 34, 45, 51 
misoprostol .................................................................. 53 pretomanid .................................................................. 17 
morphine ................................................................... 1, 2 primaquine .................................................................. 23 
moxifloxacin .......................................................... 16, 17 procaine benzylpenicillin .............................................. 12 
multiple micronutrient powder ...................................... 58 procarbazine ............................................................... 31 
multiple micronutrient supplement ............................... 54 progesterone vaginal ring ............................................ 52 
mumps vaccine ........................................................... 50 proguanil ..................................................................... 24 

 WHO Model List of Essential Medicines – 23rd List (2023) page 66 



WHO Model List of Essential Medicines – 23rd List (2023)  

propofol ......................................................................... 1 succimer ....................................................................... 4 
propranolol .................................................................. 26 sulfadiazine ................................................................. 24 
propylthiouracil ...................................................... 47, 48 sulfadoxine + pyrimethamine .................................. 23, 24 
prostaglandin E1 ......................................................... 54 sulfamethoxazole + trimethoprim ............................ 12, 24 
protamine sulfate ......................................................... 36 sulfasalazine .......................................................... 45, 59 
pyrantel ......................................................................... 7 sumatriptan ................................................................. 26 
pyrazinamide ............................................................... 16 suramin sodium ........................................................... 24 
pyridostigmine ............................................................. 50 surfactant .................................................................... 54 
pyridoxine .................................................................... 58 suxamethonium ........................................................... 50 
pyrimethamine ............................................................. 24 tacrolimus ................................................................... 26 
quetiapine ................................................................... 55 tamoxifen .................................................................... 34 
quinine ........................................................................ 23 telmisartan + amlodipine .............................................. 39 
rabies vaccine ............................................................. 50 telmisartan + hydrochlorothiazide ................................. 39 
raltegravir .................................................................... 20 tenofovir disoproxil fumarate .................................. 19, 21 
ranitidine ..................................................................... 44 terbinafine ................................................................... 41 
rasburicase ................................................................. 35 testosterone ................................................................ 46 
ravidasvir ..................................................................... 21 tetanus vaccine ........................................................... 49 
ready-to-use therapeutic food ...................................... 35 tetracaine .................................................................... 51 
realgar-Indigo naturalis formulation .............................. 31 tetracycline .................................................................. 51 
red blood cells ............................................................. 36 thalidomide .................................................................. 33 
resin-based composite (high-viscosity)......................... 60 thiamine ...................................................................... 59 
resin-based composite (low-viscosity) .......................... 60 tick-borne encephalitis vaccine .................................... 49 
retinol .......................................................................... 59 timolol ......................................................................... 51 
ribavirin ................................................................. 20, 21 tioguanine ................................................................... 31 
riboflavin ...................................................................... 59 tiotropium .................................................................... 57 
rifabutin ....................................................................... 16 tranexamic acid ..................................................... 36, 54 
rifampicin .................................................................... 16 trastuzumab ................................................................ 32 
rifapentine ................................................................... 16 triamcinolone hexacetonide ......................................... 60 
risperidone .................................................................. 55 triclabendazole .............................................................. 7 
ritonavir ....................................................................... 19 trimethoprim ................................................................ 13 
rituximab ................................................................. 6, 32 tropicamide ................................................................. 43 
rotavirus vaccine ......................................................... 49 tuberculin, purified protein derivative (PPD) .................. 48 
rubella vaccine ............................................................ 49 typhoid vaccine ........................................................... 50 
salbutamol ................................................................... 57 ulipristal ....................................................................... 52 
salicylic acid ................................................................ 42 urea ............................................................................ 42 
selenium sulfide ........................................................... 41 valganciclovir ......................................................... 20, 21 
senna ...................................................................... 3, 45 valproic acid (sodium valproate) .......................... 5, 6, 56 
sevoflurane .................................................................... 1 vancomycin ................................................................. 15 
silver diamine fluoride .................................................. 60 varenicline ................................................................... 56 
silver sulfadiazine ......................................................... 42 varicella vaccine .......................................................... 50 
simvastatin .................................................................. 41 vecuronium ................................................................. 50 
sodium calcium edetate ................................................. 4 verapamil .............................................................. 37, 38 
sodium chloride ........................................................... 58 vinblastine ................................................................... 31 
sodium hydrogen carbonate ........................................ 58 vincristine .................................................................... 31 
sodium lactate ............................................................. 58 vinorelbine ................................................................... 31 
sodium nitrite ................................................................. 4 voriconazole ................................................................ 18 
sodium nitroprusside ................................................... 39 warfarin ....................................................................... 36 
sodium stibogluconate ................................................. 22 water for injection ........................................................ 58 
sodium thiosulfate .................................................... 4, 41 whole blood ................................................................. 37 
sofosbuvir .................................................................... 21 xylometazoline ............................................................. 59 
sofosbuvir + velpatasvir ............................................... 21 yellow fever vaccine ..................................................... 49 
spectinomycin ............................................................. 12 zidovudine ................................................................... 19 
spironolactone ....................................................... 40, 44 zinc sulfate .................................................................. 46 
streptokinase ............................................................... 40 zoledronic acid ............................................................ 35 
streptomycin ............................................................... 17 

 WHO Model List of Essential Medicines – 23rd List (2023) page 67